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Globally, Uganda is one of the 30 tuberculosis (TB) and human immunodeficiency virus 
(HIV) high burden countries with high antiretroviral therapy (ART) coverage, yet 
mortality is still high among TB/HIV patients on ART. The reasons for the high mortality 
have not been fully explored. The purpose of this study was to determine the association 
between multimorbidity, age, sex, marital status, phase of TB treatment, timing of 
initiation for ART, and type of TB and mortality among TB/HIV patients on ART in 
Uganda. The health outcomes conceptual framework with 3 domains that directly or 
indirectly affect the outcome domain was used to guide the study. A quantitative cross-
sectional study design was used. The target population of 3,850 deidentified TB/HIV 
patients on ART, and data were abstracted from 2017, 2018, and 2019 medical records in 
9 out of 14 systematically selected regional hospitals in Uganda. Descriptive analysis and 
binary logistics regression were conducted. TB/HIV patients on ART with 1 or 2 or more 
multimorbidity were 1.658 times and 1.901 times more likely to die than patients with no 
multimorbidity. TB/HIV patients on ART who were separated/divorced or single were 
1.591 and 1.381 times more likely to die than married patients. The TB/HIV patients on 
ART who began ART treatment after TB treatment were 1.899 times more likely to die 
than patients who started ART before TB. The results can support social change by 
raising awareness among policymakers, national TB program staff, and health workers to 
implement approaches like patient-family-centered care to prevent deaths among TB/HIV 
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Chapter 1: Introduction to the Study 
Introduction 
Antiretroviral therapy (ART) improves tuberculosis (TB) treatment outcomes 
among patients with TB disease who are coinfected with human immunodeficiency virus 
(HIV). According to Engelbrecht et al. (2017), successful TB treatment outcomes in 
TB/HIV coinfected patients happens in those with high cluster of differentiation 4 (CD4) 
cell count (greater than 350) on cotrimoxazole and ART (Engelbrecht et al., 2017). 
Weldegebreal et al. (2018), in a study conducted in Ethiopia, noted that patients below 18 
years of age with extrapulmonary TB and on ART had improved TB outcomes. However, 
Weldegebreal et al. (2018) also noted that the treatment outcomes were not as high as 
recommended by the World Health Organization (WHO, 2018) at 90%. According to 
WHO (2018), 21 out of 27 high TB/HIV burden countries reported treatment outcomes 
below 85%, yet the global standard is 90%. Poor treatment outcomes include mortality, 
loss to follow up, failure, transfer out, and not evaluated. Mortality and loss to follow up 
constitute the poorest treatment outcomes among TB/HIV patients, with a mortality of 
9% in the Africa region. Although ART improves TB treatment outcomes among 
TB/HIV patients on ART, mortality remains high, especially in high burden TB/HIV 
countries.  
According to WHO (2018), in Uganda, mortality among TB/HIV patients is 
32/100,000, which is higher than 26/100,000 among TB patients who are HIV negative. 
High mortality among TB/HIV patients is attributed to several factors, such as delayed 
testing for TB, delayed start on ART, and anti-TB medicines (WHO, 2018). Furthermore, 
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Worku et al. (2018) noted that other common opportunistic infections that are not 
diagnosed may lead to mortality in TB/HIV patients. Generally, multimorbidity is 
associated with mortality (Academy of Medical Sciences [AMS], 2018; Oni et al., 2015; 
Smith et al., 2018). However, based on the literature, it is not clear whether 
multimorbidity, other patient characteristics, and health care processes are associated 
with mortality among TB/HIV coinfected patients on ART (AMS, 2018; Oni et al., 2015; 
Smith et al., 2018). There is a need to explore further why mortality remains high among 
TB/HIV patients on ART. In this study, based in Uganda, I explored the association of 
multimorbidity and health care processes with mortality among TB/HIV coinfected 
patients on ART. 
The study results could reveal new knowledge of multimorbidity and mortality 
among TB/HIV patients on ART, which would impact positive social change. Health 
workers might use this new knowledge to help make decisions on TB/HIV coinfected 
patients with multimorbidity to avoid mortality. The resulting data could be used in 
designing policies and guidelines on multimorbidity in Uganda. In Chapter 1, I describe 
the study’s background, problem statement, purpose of the study, research questions, and 
hypotheses. I also describe the conceptual framework, definitions, nature of the study, 
assumptions, scope and delimitations, limitations, the significance of the study to theory, 
practice, and social change. I conclude this chapter with a summary and transition. 
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Background of the Study 
TB/HIV Coinfection 
Globally, TB/HIV remains a public health problem, especially in sub-Saharan 
Africa. WHO listed 30 TB/HIV burden countries, 23 out of 30 countries are found in sub-
Saharan Africa, including Uganda (WHO, 2018). In 2005, WHO recommended 12 
TB/HIV collaborative activities, which have been adopted by countries. These broadly 
include setting up mechanisms for TB/HIV collaboration, reducing the burden of TB in 
HIV patients, and reducing the burden of HIV in TB patients (WHO, 2015). 
Additional activities include implementing TB/HIV integrated services using 
either a one-stop shop, partially integrating services, colocating services with referral 
between the HIV and TB clinics or referring TB/HV patients between TB and HIV health 
facilities (WHO, 2015). The integration ensures that TB/HIV patients are managed 
holistically (WHO, 2018). Although WHO has made recommendations to deal with the 
persistent global problem of TB/HIV, mortality among TB/HIV patients still needs more 
attention.  
Mortality in TB/HIV Coinfected Patients on ART  
It is well known that mortality is reduced in TB/HIV patients when they start 
ART early. Nagu et al. (2017) indicated that well-planned and highly supervised ART 
reduces mortality in TB/HIV patients and that death occurs early during TB treatment. 
According to Engelbrecht et al. (2017), in a retrospective study conducted in South 
Africa, successful TB treatment outcomes in TB/HIV coinfected patients happens in 
those with high CD4 cell count (greater than 350), on cotrimoxazole and ART. If well-
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supervised, ART administered early in TB/HIV patients reduces mortality among 
TB/HIV patients. Bruchfeld et al. (2015) highlighted that HIV comorbidities may be 
responsible for mortality among TB/HIV patients who develop immune reconstitution 
inflammatory syndrome (IRIS). TB IRIS is one paradoxical phenomenon that must be 
dealt with when TB/HIV coinfected patients start either ART or anti-TB medicines 
because it leads to patient deaths. 
Uganda started the test and treat policy in 2013, focusing on initiating ART within 
4 weeks of starting anti-TB treatment for TB/HIV patients. The ART coverage among TB 
patients reached 90% in 2016 and is 98% in 2018 (Ministry of Health, Uganda [MoH], 
2018). However, the mortality in TB/HIV patients is still high at 12% based on data from 
MoH (2018), and 15.5% based on research by the Makerere School of Public Health 
(2018). Even in Uganda, the reasons for high mortality are unknown, although some 
researchers have pointed out delayed testing for TB, delayed start on ART, and anti-TB 
medicines (WHO, 2018). For Uganda, mortality among TB/HIV patients on ART is still 
high, yet the reasons for the high mortality are not well known. 
Prevalence and Patterns of Multimorbidity Among TB/HIV Patients on ART 
Studies in South Africa have demonstrated a pattern of common comorbidities, 
including infectious diseases and non communicable diseases. The observed diseases 
include hypertension, diabetes, HIV, and TB. Oni et al. (2015), in peri-urban South 
Africa, studied the epidemiology of HIV, TB, and non communicable diseases 
multimorbidity and found that HIV, TB, diabetes mellitus, and hypertension accounted 
for 45% of prescription visits, thus reflecting the magnitude of multimorbidity. Pepper et 
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al. (2015) found similar results in a study conducted in Khayelitsha, South Africa, 
indicating that TB patients have a comorbidity of about 37% of hypertension and 12% for 
diabetes mellitus. Hypertension and diabetes mellitus were more prevalent among 
younger patients on ART than those not on ART.  
Epidemiological transition in developing countries is characterized by a double 
burden of infectious and non infectious diseases. The issue of multimorbidity in this 
study aligned with the epidemiological transition in developing countries (Oni et al., 
2015). Other comorbidities have been noted in TB and HIV patients, including cancers, 
malaria, pneumonia, malnutrition, and smoking (Marais et al., 2013). The standard 
patterns for TB/HIV comorbidities were TB/HIV hypertension and TB/HIV diabetes 
mellitus. The epidemiological transition may explain the double burden of infectious and 
communicable diseases from infectious to chronic disease (Oni et al., 2015). Comorbidity 
was known to be lower in TB/HIV patients on ART rather than those not on ART, but 
higher in the young age ranges of 18–35 years and 36–45 years (Oni et al., 2015). Oni et 
al. further highlighted the need for research for comorbidities among TB/HIV patients. 
Although the patterns of infectious and noninfectious diseases have been explored in 
South Africa, the patterns of multimorbidity among TB/HIV patients still need to be 
explored beyond South African studies. 
Assessment of Comorbidities/Multimorbidity 
Tools to measure comorbidities/multimorbidity have been developed focusing on 
non communicable diseases. These tools have been used to study the magnitude of 
comorbidities as an indication of the quality of life of patients, especially in developed 
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countries inpatients and patients over 65 years of age (Brown et al., 2015). These tools 
have been improved further to include non communicable diseases like HIV and TB 
(Brown et al., 2015). The tools have evolved, and now there is a functional assessment of 
chronic illness therapy–tuberculosis (FACIT) tool, which is a TB-specific tool to measure 
comorbidities and the quality of life among patients with TB (Dujaili et al., 2015).  
The health status of an individual can be assessed by counting multimorbidities. 
The number of comorbidities in an individual is associated with the likelihood of that 
individual’s death (Brown et al., 2015). The score of the count of diseases is called the 
comorbidity index. There are several comorbidity indices: Charlson comorbidity index, 
RX Risk comorbidity assessment, Elixhauser comorbidity Index, and Johns–Hopkins 
adjusted clinical group. The Charlson comorbidity index is the most common tool used to 
measure comorbidity. The tool is based on a list of 17 elements with each condition 
assigned a weight of 1 to 6, with a 0 indicating no comorbidity (Lix et al., 2016; Wallace 
et al., 2016). 
Effects of Multimorbidity on Mortality 
Although the effects of multimorbidity on mortality have been studied, mortality 
among TB/HIV patients with multimorbidity has not been well described (Samuels et al., 
2018). The effects of multimorbidity on health care are varied. According to Oni et al. 
(2015), the effects include failure for the patient to manage themselves because of many 
diseases, the need for the health care provider to have multiple skills to deal with many 
diseases, the need for several requirements, equipment, design, and infrastructure of the 
health system.. The findings indicate that the effects of multimorbidity are at different 
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levels, including patient level, health system level, and provider level, which all need 
special attention.  
Mortality is a core outcome of multimorbidity. However, the association between 
multimorbidity and mortality among TB/HIV patients on ART has not been well 
established. Globally, there is an ongoing debate on multimorbidity and the lacking 
research in all areas, especially from low-middle-income countries (Catala-Lopez, et al., 
2018; Xu et al., 2017). Studies in sub-Saharan Africa have indicated a rise in 
multimorbidity patterns and the overlap between infectious diseases and non 
communicable diseases, including, hypertension, diabetes mellitus, cancers, and others 
(Oni et al., 2015). In Uganda, the mortality in TB/HIV patients is high at 12%, despite the 
implementation of an HIV test-and-treat policy with ART coverage among TB/HIV 
patients at 98% (MoH, 2018; WHO, 2018). Understanding the relationship between 
multimorbidity, health care processes, and mortality among TB/HIV patients is crucial in 
addressing the high mortality among this population. I explored and tested the association 
between multimorbidity, health care processes, and mortality among TB/HIV coinfected 
patients on ART in Uganda. The information could contribute to the ongoing debate of 
multimorbidity health care processes and their influence on mortality among TB/HIV 
patients on ART. Health workers could use the information to make appropriate decisions 
on how to handle TB/HIV patients. Policymakers and managers could further use the 




There is high mortality among TB/HIV coinfected patients on ART in Uganda 
despite high ART coverage. According to MoH, the mortality in TB/HIV patients was 
11–12% from 2014 to 2017, despite ART coverage of 60–98% (MoH, 2018; WHO, 
2018). The reasons for the high mortality have not been explained but have been 
associated with a delay in the start of ART, delay in testing TB patients for HIV, and 
IRIS (WHO, 2018). High mortality among TB/HIV patients is still a challenge at the 
global level. According to WHO (2018), mortality among TB/HIV patients is 11%. In 
sub-Saharan Africa, mortality in TB/HIV patients is 9%, whereas in Uganda, it is 12% 
(WHO, 2018). According to Mchunu et al. (2016), Swaziland has recorded high mortality 
among TB/HIV patients at 14%. The reasons for mortality are not well understood, but 
the issues explained relate to failure to decentralize treatment from doctors to nurses 
(Mchunu et al., 2016).  
Global studies have indicated that multimorbidity is an increasing concern and is 
associated with low quality of care and death. In sub-Saharan Africa, multimorbidity is 
increasing, as seen from studies conducted in South Africa (Oni et al., 2015). The 
existing studies on mortality and TB/HIV coinfected populations on ART have indicated 
inadequate information on the association of multimorbidity and mortality among 
TB/HIV coinfected patients on ART (Mchunu et al., 2016; Oni et al., 2015; Pepper et al., 
2015). There is inadequate information about multimorbidity in middle-income and 
lower-income countries, including Uganda (Catala-Lopez et al., 2018). Mortality is a 
known core outcome of multimorbidity. The need to study multimorbidity, health care 
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processes, and their association to mortality in Uganda was paramount (Catala-Lopez et 
al., 2018; Smith et al., 2018; Xu et al., 2017). The purpose of the study was to test and 
analyze the association between multimorbidity, health care processes, and death among 
TB/HIV patients on ART. The independent variables were multimorbidity, age, sex, 
marital status, phase of TB treatment, time of initiation of ART, and type of TB. The 
dependent variable was mortality. 
Purpose of the Study 
The purpose of this quantitative study was to test and analyze the association 
between multimorbidity, health care processes, and mortality among TB/HIV patients 
treated with ART in Uganda. The independent variables were multimorbidity, measured 
as yes or no. Multimorbidity in this study meant patients with TB/HIV with two or more 
diseases in addition to TB and HIV. Examples of these diseases are diabetes mellitus, 
hypertension, malnutrition, pneumonia, and cancers. The other independent variables 
were age, sex, marital status, the type of TB, phase of TB treatment, and initiation timing 
for ART measured as yes or no. The dependent variable was mortality, measured as yes 
or no.  
Research Questions and Hypotheses 
In this study, I addressed the following research questions with corresponding null 
and alternative hypotheses: 
RQ1: What is the association between multimorbidity (disease clusters) and 
mortality among TB/HIV patients on ART? 
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H01: There is no association between multimorbidity (disease clusters) and 
mortality among TB/HIV patients on ART. 
Ha1: There is an association between multimorbidity (disease clusters) and 
mortality among TB/HIV patients on ART 
RQ2: What is the association between demographic factors (sex, age, and marital 
status) and mortality among TB/HIV patients on ART? 
H02: There is no association between demographic factors (sex, age, and marital 
status) and mortality among TB/HIV patients on ART. 
Ha2: There is an association between demographic factors (sex, age, and marital 
status) and mortality among TB/HIV patients on ART. 
RQ3: What is the association between the phase of TB treatment (initiation and 
continuation) and mortality among TB/HIV patients on ART? 
H03: There is no association between the phase of TB treatment (initiation and 
continuation) and mortality among TB/HIV patients on ART. 
Ha3: There is an association between the phase of TB treatment (initiation and 
continuation) and mortality among TB/HIV patients on ART. 
RQ4: What is the association between the time of initiation of ART (before the 
start of TB treatment and after the start of TB treatment) and mortality among TB/HIV 
patients on ART? 
H04: There is no association between the time of initiation of ART (before the 
start of TB treatment and after the start of TB treatment) and mortality among 
TB/HIV patients on ART. 
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Ha4: There is an association between the time of initiation of ART (before the 
start of TB treatment and after the start of TB treatment) and mortality among 
TB/HIV patients on ART. 
RQ5: What is the association between type of TB (pulmonary bacteriologically 
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality among 
TB/HIV patients on ART? 
H05: There is no association between the type of TB (pulmonary bacteriologically 
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality 
among TB/HIV patients on ART. 
Ha5: There is an association between the type of TB (pulmonary bacteriologically 
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality 
among TB/HIV patients on ART. 
Using binary logistics regression, I tested and analyzed the associations between 
multimorbidity, sex, age, marital status, type of TB, phase of TB treatment, the timing of 
initiation for ART, and mortality among TB/HIV patients on ART.  
Conceptual Framework 
The conceptual framework for this study was the health outcomes conceptual 
framework. The health outcomes conceptual framework relates to a complex interplay 
between a health system’s 4 domains, patient factors, care path, and health outcomes 
(Canadian Institute for Health Information, 2008; Sbarigia et al., 2016). The health 
outcomes framework has its origins in the Donabedian model used for quality of care 
improvement developed in 1967 and implemented in the 1980s (1980, 1986, and 1988). 
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The Donabedian model includes three levels: (a) the structure or context, which is the 
setting for health care delivery; (b) the process where medical interventions are 
implemented; and (c) the outcome, which is the impact of health outcomes (Canadian 
Institute for Health Information 2008; Sbarigia et al., 2016). Apart from its use in quality 
improvement, this framework has been used in the study of processes in health care 
delivery settings and how the processes impact health outcomes.  
The framework is also related to outcomes research studies in which researchers 
focused on chronic issues like mental health and diabetes. The framework has also been 
used in the Hepatitis C outcomes framework (Canadian Institute for Health Information 
2008; Sbarigia et al., 2016). Based on its simplicity in studying patient-level outcomes, 
the outcomes conceptual framework was used to explore the relations between patient 
characteristics, multimorbidity, and mortality, contributing to patient-level outcomes. 
Using this health outcome conceptual framework, I focused on testing and analyzing the 
association of multimorbidity, age, sex, marital status, phase of TB treatment, time of 
initiation on ART, and type of TB with mortality among TB/HIV coinfected patients on 
ART in Uganda (Bates et al., 2015). The health outcomes framework was the most 
appropriate framework to use because it can be used to explore the relation of mortality 
and aspects of health structure, patient characteristics, and care process (Canadian 
Institute for Health Information, 2008). 
The critical elements of the framework are the structure or context (health care 
system structure or context), patient factors, care path, and health outcomes (Canadian 
Institute for Health Information, 2008; Sbarigia et al., 2016). The health care system 
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structure is the mechanism patients obtain health care through. There are providers, 
clinics, and records, so patient characteristics, provider characteristics, and surveillance 
are necessary. Patient factors include social demographics (age, gender, ethnicity, 
education, income, marital status, and socioeconomic attributes); risk factors like 
smoking, drinking, physical activity and diet; and expectations or preferences of the 
patient. The care path includes interventions. Interventions are what is given to the 
patient to change the health care status, including prevention, treatment, and care. The 
processes of care in this study were anti-TB medicines, ART, and cotrimoxazole 
preventive therapy. The health outcomes were the status achieved after the 
implementation of interventions. Health outcomes may be either patient-related outcomes 
or health-system outcomes. Patient-related outcomes include health status, health-related 
measures, and non-health-related measures. The following are examples of the health-
related measures, quality-adjusted life years, disability-adjusted years, health-related 
measures like hospital admissions, complications, or test results, whereas non-health-
related measures include patient satisfaction. At the population level, health system 
performance measures apply at the national level, and the health outcomes include 
morbidity prevalence and mortality (Canadian Institute for Health Information, 2008; 
Sbarigia et al., 2016). In this study, I focused on mortality, which is under patient-level 
health outcomes (Brown et al., 2016). 
The health outcomes conceptual framework provided a logical framework for 
studying multimorbidity among TB/HIV patients on ART. The conceptual framework 
also offered a line of thinking from the structure processes to outcomes, emphasizing 
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what happens rather than what went wrong, as highlighted by Donabedian. That kind of 
thinking is followed in the quality of care to improve patient health status and, therefore, 
multimorbidity. Based on this framework, the health outcomes and the health-related 
outcome (mortality) were the dependent variables. The other categories, like patient 
characteristics, formed the outcome variable or independent variable (multimorbidity). 
Several tools, like the Charlson comorbidity index tool and specific TB tools like the 
FACIT TB tool, could be used to measure TB-related comorbidities (Dujaili et al., 2015; 
Mamani et al., 2014). TB/HIV documents were reviewed to confirm the different patient 
characteristics, including multimorbidity. The health outcomes conceptual framework 
was used to guide the study on multimorbidity, healthcare processes versus mortality 
among TB/HIV patients on ART in Uganda. The data analyzed were related to the flow 
of the framework.  
Nature of the Study 
In this study, I used quantitative research methods with a cross-sectional design, 
coupled with a retrospective review of medical records to retrieve secondary data 
(Rudestam & Newton, 2015; van den Akker et al., 2001). Many studies have been 
conducted on comorbidity and multimorbidity. Researchers have used cross-sectional 
studies with a review of records (Oni et al., 2015; Peltzer, 2018; Pepper et al., 2015, 
Weimann et al., 2016). Furthermore, Catala-Lopez et al. (2018) noted that in various 
systematic studies researchers used a cross-sectional design to study multimorbidity in 
different countries. Cross-sectional studies are being used in the description of variables, 
description distribution of multimorbidity patterns, and examination of associations 
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between predictors and outcomes (Hulley, 2007). Also, cross-sectional studies could be 
used to provide information on those with a disease or a condition at a given point in time 
(Hulley, 2007).  
To ensure external validity, several issues that affect generalization, like selection 
bias, were dealt with by ensuring a representative sample was selected from the regional 
referral hospitals in Uganda that handle TB/HIV patients. The regional referral hospitals 
in the sample were chosen systematically. All TB/HIV patients on ART were included in 
the sample to make the minimum required sample for each facility. An adequate sample 
was maintained by calculating the sample size required to ensure that the study has 
adequate power (Rudestam & Newton, 2015). The data collected included 
multimorbidity, sex, age, marital status, type of TB, phase of TB treatment, timing of 
initiation for ART, and mortality data. The selected variables were based on findings 
from other studies of comorbidities and multimorbidity in sub-Saharan Africa (Bates et 
al., 2013; Creswell, 2011, Oni et al., 2015; Pepper et al., 2015).  
After authorization by the Walden University Institutional Review Board (IRB; # 
01-31-20-0226229), Makerere University Higher Degrees Research Ethical Committee 
(#772), the Uganda National Council of Science and Technology (#HS692ES), the MoH, 
and regional referral hospitals, the following were accessed for data abstraction: TB 
registers, ART cards, patient files, and electronic registers. All patient data were 
deidentified. I conducted quantitative binary regression to test the associations between 
multimorbidity, sex, age, marital status, type of TB, phase of TB treatment, timing of 




Antiretroviral therapy (ART): A combination of antiretroviral drugs that suppress 
HIV and stop the progression of HIV disease (WHO, 2015).  
Diabetes mellitus: Diabetes leads to raised blood sugar called hyperglycemia and 
is a disease of chronic nature (WHO, 2015). 
Health care system: A mechanism through which patients get health care from 
health care providers (Canadian Institute for Health Information 2008; Sbarigia et al., 
2016). 
Health outcomes: Changes in health that result from the implementation of 
interventions. Health outcomes may be patient-related outcomes or health system 
outcomes (Canadian Institute for Health Information 2008; Sbarigia et al., 2016).  
Hypertension: A situation in which an individual has high or raised blood 
pressure. Normal blood pressure is less than 120/80 mm Hg. Elevated blood pressure has 
systolic readings between 120-129 and diastolic readings less than 80; Stage 1: Systolic 
between 130-139 or diastolic between 80-89;while Stage 2: Systolic at least 140 or 
diastolic at least 90 mm Hg; a hypertensive crisis: Systolic over 180 and/or diastolic over 
120 (Carey & Whelton, 2018). 
Multidrug-resistant TB (MDR-TB): TB resistant to at least rifampicin and 
isoniazid, the two most effective anti-TB drugs (WHO, 2015).  
Multimorbidity: Existence of more than one medical condition or situation in an 
individual (AMS, 2018). 
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Noncommunicable diseases: Noninfectious health conditions typically caused by 
genetic, environmental, and lifestyle factors (Bates et al., 2015). 
Patient factors: Characteristics that include social demographics (age, gender, 
ethnicity, education, income, marital status and social, economic attributes); risk factors 
like smoking, drinking, physical activity and diet; and expectations or preferences of the 
patient (Sbarigia et al., 2016). 
Process of care: Interventions, including prevention and care interventions 
(Sbarigia et al., 2016). 
TB/HIV coinfected patients: TB disease occurring in someone infected with HIV 
(WHO, 2015). 
Assumptions 
The first assumption in this study was that all HIV patients are screened for TB, 
and all those who had TB were diagnosed. This assumption was based on the WHO 
recommendation that all HIV patients be screened for TB at every health facility visit. 
Another assumption was that all multimorbidity in TB/HIV coinfected patients had been 
recorded on the ART cards and that all records were as complete as possible. At 
hospitals, there are dedicated records officers who fill in the information in the Unit TB 
register and the ART cards. Based on ART clinic practice, the record details of any 
multimorbidity and medications are recorded on the ART card. A third assumption was 
that all TB/HIV patients are administered both anti-TB medicines and ART. This 
assumption was based on the WHO recommendation adopted in 2013 in Uganda. All 
TB/HIV patients should be started on anti-TB treatment immediately after diagnosis and 
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ART within 2 months or  as soon as they can tolerate ART and based on the recent test-
and-treat policy (WHO, 2016). However, it was beyond the scope of this study to prove 
that all TB/HIV coinfected patients in the communities are diagnosed and administered 
anti-TB treatment and ART.  
Scope and Delimitations 
The specific aspects of the research problem addressed in the study were related 
to the selected patients’ characteristics. The characteristics included gender, age, type of 
TB, multimorbidity (diabetes mellitus, hypertension, malnutrition, pneumonia, cancer), 
and health care processes like phase of TB treatment and timing of initiation for ART 
among TB/HIV patients on ART. Multimorbidity may be associated with mortality. The 
multimorbidity, health care processes, and mortality among TB/HIV patients on ART 
were studied to understand the relationship and support remedial actions. 
The study participants included all TB/HIV patients on ART. The study excluded 
all TB/HIV patients on ART who had missing outcome variables. I used the health 
outcome conceptual framework for this study, a broad framework with some aspects not 
included in the study. The framework has three levels, the structure or context 
representing the health care delivery setup, the process representing how medical 
interventions occur, and the health outcomes. However, in this study, only parts of the 
three levels of the conceptual framework were studied. The parts of the conceptual 
framework that were studied included patient characteristics, which is part of the context, 
and mortality as the health outcome, the processes of the health outcomes, and mortality 
as health outcomes. The outcomes framework is so broad that some parameters were not 
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studied. Population-level outcomes, which include mortality rates and morbidity rates, 
were not studied. Other elements not studied in the context included the provider 
characteristics, the surveillance system, and clinic characteristics. This study is 
generalized to a study population in Uganda of TB/HIV patients on ART, focusing on 
multimorbidity and mortality.  
Limitations 
One of the critical limitations of this study was missing data or incomplete 
records encountered during data retrieval. To ensure that this limitation was minimized, 
patients were oversampled to cover for these data gaps. There could have been a threat of 
statistical validity, in which the sample size is too small to show any effect (Harris, 
2016). I calculated the sample size to overcome statistical threat validity due to the small 
sample size. I ensured that more participants beyond the calculated sample were included 
in the sample to cater for missing data. During analysis, this adequate sample was used to 
make conclusions. 
Significance of the Study 
Significance to Theory 
The types of multimorbidity among TB and HIV patients are known. However, 
the multimorbidity and its association with mortality among TB/HIV coinfected patients 
on ART have not been explicitly studied (AMS, 2018). The results of this study highlight 
the associations between multimorbidity, health care processes, and TB mortality among 
TB/HIV patients on ART in Uganda. The results of the study can contribute to new 
knowledge regarding multimorbidity and mortality among TB/HIV patients on ART.  
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Significance to Practice 
Testing the associations between multimorbidity, health care processes, and 
mortality has helped to highlight the critical multimorbidities associated with mortality. 
In alignment with WHO’s strategy to end TB and the era of comorbidity, it is essential to 
know and manage the multimorbidities appropriately for TB/HIV patients on ART 
(WHO, 2016). Health providers could use this study’s results to understand common 
multimorbidities among TB/HIV patients on ART. The results could also provide insights 
to national TB program managers to plan appropriately (human resources, medicines, 
infrastructure, training) in managing and following up TB/HIV patients with various 
multimorbidities (WHO, 2016). 
Significance to Social Change 
Regarding positive social change, this study’s results could be disseminated to the 
national TB program and organizations working in communities to plan, manage, 
monitor, and improve the way multimorbidity is managed among TB/HIV individuals 
and their families and the general community. Managers could use the results to improve 
patient health, including networks of TB patients coinfected with TB and who have other 
comorbidities. The results could also contribute to policies on multimorbidity because it 
is a new area on the global scene and is likely to be recognized in developing countries. 
Summary and Transition 
In TB and HIV patients, multimorbidity is associated with poor health outcomes, 
regardless of whether they are on ART. There is still inadequate information on the 
prevalence and consequence of multimorbidity among TB/HIV coinfected patients 
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initiated on ART (Mchunu et al., 2016; Pepper et al., 2015). The purpose of this study 
was to test the association of multimorbidity, health care processes, and mortality among 
TB/HIV patients on ART in Uganda. The independent variables were multimorbidity, 
phase of TB treatment, initiation of ART after the start of TB treatment, and type of TB. 
The dependent variable was mortality. I used a cross-sectional study design with 
quantitative methods and secondary data review (Rudestam & Newton, 2015; van den 
Akker et al., 2001). I analyzed and tested the association between mortality and 
multimorbidity among TB/HIV patients on ART in Uganda. I analyzed the associations 
between the independent variables and dependent variables using binary logistics 
regression. I conducted a multivariate analysis using binary logistics regression (van den 
Akker et al., 2001). 
I am hopeful that managers, policymakers, and community organizations might 
use the results of this study to improve practice in health facilities and communities. 
Further, this study’s results are likely to impact social change so that patients and 
networks with multimorbidity are managed by the health care system and in 
communities. In Chapter 2, I expound on the sections covered in Chapter 1 by reviewing 
the literature in detail to deepen the understanding about TB/HIV, exploring available 





Chapter 2: Literature Review 
Introduction  
Uganda is a high-burden country for TB/HIV and is among the 30 TB/HIV high-
burden countries with poor TB treatment outcomes. The country still records mortality of 
about 13% among TB/HIV coinfected patients on ART, despite high ART coverage 
(MoH, 2018; Musaazi et al., 2019; WHO, 2018). A further review of current studies 
shows that mortality is a core outcome of multimorbidity. The studies also highlight the 
inadequate literature on multimorbidity in middle- and low-income countries (Catala-
Lopez et al., 2018; Smith et al., 2018; Xu et al., 2017). The studies reviewed on TB/HIV 
had inadequate information on the association of multimorbidity and mortality among 
TB/HIV coinfected patients on ART (Mchunu et al., 2016; Oni et al., 2015; Pepper et al., 
2015). 
Bates et al. (2015) and WHO (2018) have indicated that 
comorbidity/multimorbidity could be contributing to mortality among TB/HV patients 
globally. Oni et al. (2015) and Peltzer (2018) have suggested that comorbidity or 
multimorbidity could be associated with mortality among TB/HIV patients in South 
Africa. Studies conducted in Uganda show that high mortality among TB/HIV may be 
associated with extrapulmonary TB, low CD4 cell count, late presentation, several 
comorbidities, and low Karnofsky score (Kirenga et al., 2014, Musaazi et al., 2019). All 
the studies I reviewed indicate that multimorbidity among TB/HIV patients may be 
associated with mortality. However, none of these studies showed any statistical 
significance that comorbidity or multimorbidity contributes to mortality among TB/HIV 
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patients on ART (Bates et al., 2015: Kirenga et al., 2014; Musaazi et al., 2019; Oni et al., 
2015). This finding highlights the need for research on the association between mortality 
and multimorbidity among TB/HIV patients on ART in Uganda.  
The purpose of this study was to test and analyze the association between 
multimorbidity, health care processes, and mortality among TB/HIV patients on ART. 
The independent variables were multimorbidity, age, sex, marital status, type of TB, 
phase of TB treatment, and timing of initiation for ART. For this study, a patient had 
multimorbidity if they had any two diseases in addition to TB and HIV. Examples of 
these diseases are diabetes mellitus, hypertension, malnutrition, pneumonia, and cancers. 
Multimorbidity was measured as yes or no. The dependent variable was mortality.  
This chapter includes the literature search strategy, the conceptual framework, and 
the literature review. The literature review consists of descriptions, evidence, and 
synthesis of the current literature for the last 5 years and classic or relevant literature 
beyond 5 years. The literature review includes topics on TB/HIV coinfection, mortality in 
TB/HIV coinfected patients on ART, prevalence, and patterns of multimorbidity among 
TB/HIV patients on ART. Also, the literature review includes an assessment of 
multimorbidity, the effects of multimorbidity on mortality, and a gap in the mortality and 
multimorbidity among TB/HIV patients on ART. The last section of this chapter includes 
a summary and conclusions about key findings and a transition to Chapter 3. 
Literature Search Strategy 
I searched electronic databases for individual articles in English, using Google 
search engine, Google Scholar, and Thoreau from Walden University. The electronic 
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databases included PubMed, CINAHL, Dissertations & Theses at Walden University, 
EBSCO ebooks, MEDLINE with full text, Open Library, Science Direct, SAGE 
Knowledge, Thoreau Multi-Database Search, and World Health Organization database. 
Keywords used during the search included multimorbidity, comorbidity, TB/HIV, ART, 
treatment of multimorbidity, opportunistic infections, prevention of comorbidities, 
TB/HIV integration, TB, TB/HIV Mortality, TB/HIV deaths, TB/HIV outcomes 
multimorbidity conceptual framework, patient outcomes conceptual framework, 
multimorbidity, and mortality. 
The main articles included in this literature review were published between 2016 
and 2020 found mainly in peer-reviewed journals. The journals include AIDS Research 
and Treatment, Journal of AIDS and HIV Research, Journal of Infectious Diseases, The 
Lancet, Transactions of the Royal Society of Tropical Medicine and Hygiene, and the 
Biomed Central Pulmonary Medicine open access New England Journal of Medicine, and 
PLoS ONE. I also reviewed articles from the International Journal of Tuberculosis and 
Lung Disease, Public Health Action, the Journal of the International Association of 
Providers of AIDS Care, the AIDS Journal, International Journal of Mycobacteriology, 
and Journal of Acquired Immune Deficiency Syndromes. Also, journals from sub-Saharan 
Africa and India were reviewed: the South African Medical Journal, the Ethiopian 
Journal of Health Development, and the Indian Journal of Medical Research. I accessed 
the relevant articles and applied the snowball method with Google Scholar to access other 
papers that have referenced the article to obtain more articles related to multimorbidity 
and TB/HIV outcomes. Manuscripts published between 2016 and 2020, within 5 years of 
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expected publication, were included. Also, a few relevant classical references outside the 
5 years were included.  
The identified items were entered into the Zotero database in different folders. 
The conceptual framework and all variables had folders in Zotero to ease the writing 
processes. Using Zotero, I searched for names of PDF articles that were downloaded but 
had not been appropriately cited. The Zotero software was used to make corrections to 
the references that were poorly labeled. Cleaning the Zotero database was coupled with 
removing duplicates and checking for proper referencing using APA style. The references 
for excerpts extracted from websites were entered, and I continued to review and remove 
redundant articles while adding relevant items until the literature review was complete. 
All folders were merged to form one folder and the reference list was produced using 
APA style. 
Conceptual Framework 
The health outcomes conceptual framework has been used to guide the framework 
of this study. The health conceptual framework has been used in research outcomes and 
health services research. The framework has four domains that include (a) characteristics 
of the health system or health care system, (b) patient characteristics, (c) 
care/interventions path or process of care, and (d) outcomes (Canadian Institute for 
Health Information, 2008; Sbarigia et al., 2016). According to Sbarigia et al. (2016), the 
health system and patient factors are direct predictors of care path (the process of care), 
which is, in turn, a direct predictor of health outcomes. Also, the patient factors are direct 
predictors of health outcomes (Sbarigia et al., 2016). 
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In this section, I explain the four domains of the health outcomes conceptual 
framework. The characteristics of the health system or health care system structure have 
the process, structure, and quality related factors; these include clinic characteristics and 
provider characteristics. The patient characteristics have sociodemographic factors (age, 
gender, ethnicity, income, education, marital status, socioeconomic status), risk factors 
(genetics; behavior, e.g., smoking, drinking, physical activity and diet; personal 
resources, e.g., social support, life stress), laboratory, clinical and health status, and 
multimorbidity. For care/interventions, path or process of care including preventive, 
pretreatment, treatment, and treatment monitoring. The outcomes include patient-related 
issues and health system-related consequences. The patient-related results include health 
status: e.g., HRQOLTB treatment outcomes (mortality, LTFU, cure + completed = TSR, 
non evaluated, failure), the health related (proxy measure of the health status), e.g., 
hospital admissions, complications, increased health service utilization and non health-
related, e.g., patient satisfaction. The health system performance-related outcomes 
include mortality rates and morbidity rates. Figure 2 shows the health system’s four 
domains, patient factors, care path and health outcomes, and the relations and how they 





The Health Outcomes Conceptual Framework 
 
Comorbidities as health outcomes are significant in three significant areas: (a) 
clinical care, (b) epidemiology and public health, and (c) health service planning and 
financing (Valderas, 2009). Comorbidities usually need to be part of the patient outcomes 
measuring quality of life because it defines health status. In the early 2000s, 
comorbidities related to TB were measured using general instruments like the Short Form 
36 (SF36), Charlson comorbidity index, and the WHO tool (Brown et al., 2015). Specific 
TB tools are now available to measure TB-related comorbidities—the FACIT-TB 
(Dujaili et al., 2015; Mamani et al., 2014). Based on this framework, the health outcomes 
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and health status (comorbidities) were the dependent variable, and the other categories 
like patient characteristics formed the outcome variable or independent variable.  
The health outcomes conceptual framework has elements developed earlier on by 
the Donabedian quality of care framework with a structure, process, and outcomes 
(Canadian Institute for Health Information, 2008). Donabedian model refers to the 
structure as a setting for care delivery, while the process is the medical interventions and 
outcome as the impact on health status outcomes. The outcomes are the result of the 
effect of the structure and process. Donabedian’s model has been used to measure and 
evaluate the quality of care and health systems’ performance (Canadian Institute for 
Health Information, 2008; Donabedian, 2005). 
The earlier conceptual framework by Donabedian was later used in research study 
outcomes and by the Canadian Institute for Health Information to focus on the four 
domains. The four areas include the health system structure, the patient characteristics or 
factors, the care path, and outcomes (Canadian Institute for Health Information, 2008; 
Donabedian, 2005; Sbarigia et al., 2016). The framework is also related to outcomes 
research studies focusing on chronic studies and the hepatitis C outcomes framework 
(Canadian Institute for Health Information 2008; Sbarigia et al., 2016). Although the 
framework mentions these social determinants of health, it does not exhaust them. It does 
not include social determinants for health inequities and political and structural 
determinants as explained in the new commission for social determinants of health 
(CSDH) WHO conceptual framework (WHO, 2010). The WHO conceptual framework 
includes the structural determinants, the social determinants of health inequities and 
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social determinants of health and how these affect equity in health and well-being, also 
referred to as health outcomes (WHO, 2016). In the WHO conceptual framework, the 
health system is one of the social determinants of health. The outcomes conceptual 
framework is still relevant because of its simplicity in studying the patient level outcomes 
and, in particular, comorbidities, a contributor to the health status in an individual patient. 
The critical statements and definitions of the health outcomes conceptual 
framework include the health system, the patient factors, care path, and health outcomes. 
The health care system structure: This is a mechanism through which patients get health 
careThe patient factors: the patient characteristics include social demographics (age, sex, 
ethnicity, education, income, marital status, and social, economic attributes), risk factors 
like smoking, drinking, physical activity and diet, and expectations or preferences of the 
patient. The care path includes interventions; Interventions are what is given to the 
patient to change the health care status, and this includes prevention, treatment, and care. 
The interventions in this study are anti-TB medicines, ART, and cotrimoxazole 
preventive therapy. 
The health outcomes are status achieved after the implementation of interventions 
(Smith et al., 2017). Health outcomes may be either patient related outcomes or health 
system outcomes. Patient related outcomes include health status, health-related measures, 
and non-health related measures (Sbarigia et al., 2016). The examples of the health-
related measures include quality-adjusted life years, disability- adjusted years; health-
related measures like hospital admissions, complications, or test results; while non-health 
related measures like patient satisfaction. At the population level, health system 
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performance measures apply at the national level, and the health outcomes include 
morbidity prevalence and mortality (Canadian Institute for Health Information, 2008; 
Sbarigia et al., 2016).  
Outcomes research is varied and focuses on quality, the effectiveness of health as 
measured by attainment of specified outcome (Jefford et al., 2003; Shah et al., 2013). The 
outcomes include survival, disease status, complications, HRQOL, patient preferences, 
quality of care, costs, and mortality. In the past, the health outcomes conceptual 
framework has been used in research studies like the management of hepatitis C virus 
infection in virology. The framework has also been utilized in the study of chronic 
diseases like diabetes in noncommunicable diseases, cancers in oncology, and depression 
in mental health (Oni et al., 2015; Sbarigia et al., 2016). Earlier studies done in the 2000s 
indicated that the outcomes research was used to assess well-being and satisfaction and 
economic analysis. The economic analysis includes cost outcome, cost effectiveness, and 
cost utility. The models used in decision analysis should link research results, patient 
preferences, and population data (Jefford et al., 2003; Shah et al., 2013). The framework 
has been used in clinical trials and other studies. The benefits of outcomes research are 
varied, including the consumer, health care provider, health care organization 
management, and government (Jefford et al.,2003; Shah et al., 2013). 
The benefits include increased participation in decision making for consumers, 
certainty about interventions by providers, use of the most cost effective interventions by 
health care organizations, and for governments to be able to plan, save on costs, using 
effective medicines and research areas (Jefford et al., 2003; Shah et al., 2013). Using this 
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health outcome conceptual framework, I tested and analyzed the association between 
multimorbidity, health care processes, and mortality among TB/HIV patients on ART in 
Uganda. The health outcomes framework was the most appropriate framework to use 
because it could be used to explore the relation of multimorbidity with mortality among 
TB/HIV patients on ART (Canadian Institute for Health Information, 2008, Sbarigia et 
al., 2016). 
Literature Review 
In this section, I describe the constructs of interest for this study, the chosen 
methodology, and methods that are consistent with the scope of the study. The constructs 
include the TB/HIV epidemiology, TB/HIV collaboration and the integration of TB/HIV 
services, TB/HIV and ART, HIV and TB drug interactions and adverse effects, Mortality 
among TB/HIV patients, multimorbidity among TB/HIV patients, determinants and 
patterns of multimorbidity, measures of multimorbidity, and later the methods and 
methodology consistent with this study. 
TB/HIV Epidemiology  
In 1993, the WHO declared the DOTS strategy to deal with an increasing TB 
global epidemic (WHO, 2016). The DOTS strategy was underpinned by five components 
that included political commitment, diagnosis through microscopy, administration of 
standardized short course chemotherapy through directly observed therapy, regular 
supply of anti-TB medicines, recording and reporting (WHO, 2016). Globally, countries 
started implementing the DOTS strategy to detect 70% of the TB cases and cure 85% of 
the identified TB patients. There was a noticeably increased TB notifications trend, and 
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by 2015, countries had saved 43 million people with TB. However, the increasing TB 
patients’ trend was associated with HIV, especially in the 22 high burden countries. It 
was evident that the DOTS strategy was not adequate to control TB and WHO replaced 
the DOTS strategy with the STOP TB strategy, which had additional components to deal 
with the TB/HIV burden and the rising MDR TB (WHO, 2016). 
To date, HIV and TB constitute the high burden diseases in low resource settings, 
especially in sub-Saharan Africa (Bruchfeld et al., 2015; WHO, 2018). WHO has selected 
the 30 TB/HIV high burden countries focusing on the TB/HIV epidemic in these 
countries, as showed in the End TB strategy (WHO, 2018). HIV increases the risk of 
developing TB to 20 to 40-fold and causes 25% of deaths in TB patients (Bates et al., 
2015). The TB/HIV coinfection in countries like sub-Saharan Africa was about 70%, and 
it was inevitable the TB/HIV epidemic needed to be dealt with (Bruchfeld at al., 2015). In 
the TB high burden areas in low resource settings, HIV increases susceptibility to TB, 
reinfection with TB, and also reactivation of TB. HIV increases progression to TB, while 
TB increases the progression from HIV infection to AIDS.  
TB/HIV Collaboration and the Integration of TB/HIV Services 
To control the dual epidemic, in 2005, WHO developed a TB/HIV framework 
with 12 collaborative activities. The three objectives of the TB/HIV collaboration were to 
establish mechanisms for TB/HIV collaboration, reduce the burden of TB in HIV patients 
and lessen the burden of HIV in TB patients (Ford, & Getahun, 2015; WHO, 2016). 
Countries have used this framework to test over 80% of TB patients for HIV and start 
over 30 % of TB /HIV patients on ART (Ford, & Getahun, 2015; WHO, 2018). 
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Individual countries like Uganda have tested above 90% of TB patients for HIV and 
started over 80% of TB/HIV patients on ART (WHO, 2018) 
Integration of TB/HIV services has been known to improve TB treatment 
outcomes (Mchunu et al., 2016; Musaazi et al., 2019). Five models of integration have 
been identified by several studies based on entry at either the TB or HIV service point 
with a referral for a service at the other aspect and then offering both services at the same 
point in Uganda (Legido-Quigley et al., 2013). Integration of TB/ HIV services has been 
found to vary based on the different model’s TB/HIV service delivery from full 
segregation of services through partial integration with referral to full integration. Since 
no one size fits all, the different models have advantages and disadvantages. The model 
with complete segregation with a referral is easy to implement. However, the model has 
risks of losing patients, while the one with full integration needs more space and human 
resources hosted at the same site. Although the service delivery models have not been 
comprehensively compared in the different studies to determine the best model for 
delivering TB/HIV services. Uyei et al. (2012) found that co-location of services is 
necessary but not sufficient for comprehensive TB/HIV service delivery to occur. Also, 
treatment outcomes amidst TB/HIV integration affect comorbidities, side effects, delay of 
patients to access treatment, low serum levels, low patient weight, previous TB treatment, 
and knowledge on TB treatment (Mchunu et al., 2016; Musaazi et al., 2019). Useful 
indicators for monitoring integration, like mortality, need to be selected (Mchunu et al., 
2016). The researchers and practitioners should be extending the collaborative TB/HIV 
framework to handle multimorbidity (Oni et al., 2015; WHO, 2018). 
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TB/HIV and ART 
In many studies, ART has been shown to reduce mortality and improve TB 
treatment outcomes by preventing opportunistic infections and restoring immunity with 
lifelong viral suppression (Mchunu et al., 2016; WHO, 2018). The TB deaths in TB/HIV 
coinfected patients, although not sure, seems to be an indicator that can be used to 
monitor TB/HIV integration (Ansa et al., 2012). Clinical studies indicate that ART does 
not entirely restore immunity in HIV patients and, therefore, a risk of developing 
comorbidities, especially in advanced age (WHO, 2018). Some studies have shown that 
mortality is still high in TB/HIV patients on ART. The mortality may be due to 
comorbidities and late treatment initiation (Mchunu et al. 2016, Nansera et al., 2012). 
Other studies indicate that ART has a protective effect against death in TB/HIV patients 
on ART (Pepper et al., 2015). Also, Oni et al. (2015) found that in South Africa, HIV 
patients who were on ART had a lower comorbidity index than those not on ART (Oni et 
al., 2015). Although ART has protective effects in TB/HIV patients on ART, there is a 
need to determine why some TB/HIV patients on ART still die (Mchunu et al., 2016, 
Pepper et al., 2015). 
HIV and TB Drug Interactions and Adverse Effects 
Drug interactions commonly occur in TB/HIV patients on rifampicin. Rifampicin 
interacts with nevirapine and efavirenz due to induction of CYPP50. This induction 
reduces the bioavailability of both these drugs (Bruchfeld et al., 2015). To mitigate this 
effect, the best anti-TB drug to use is rifabutin or the use of efavirenz. Adverse effects are 
common in TB/HIV patients on anti-TB treatment and HAART. Adverse effects also 
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occur with the use of anti-TB together with ARVs. The common side effect is 
hepatotoxicity caused by Rifampicin and Isoniazid; also, ARVs cause this. So, the double 
effect may be magnified in some patients causing mortality. HIV patients who start 
ARVs late usually experience IRIS; this leads to worsening TB signs and symptoms and 
deterioration of the radiographic features on a chest X-ray. Lymphadenopathy is also 
common. Treatment with corticosteroids helps in managing the IRIS. 
Mortality Among TB/HIV Patients 
The initiation of ART among TB/HIV patients led to the improvement of 
treatment outcomes. However, despite ART initiation among TB/HIV patients, the 
mortality among these patients is high (Mchunu et al., 2016; WHO, 2018). In Swaziland, 
the evaluation of the 2010–2013 cohort showed similar findings where about 13% of 
TB/HIV coinfected patients were dying despite ART (Mchunu et al., 2016). Similar 
findings have also been found in Uganda by Musaazi et al. (2019), where about 10% of 
TB/HIV coinfection are still dying. However, in all the studies, the risk factors associated 
with the high case fatality rates are not well known. 
Multimorbidity Among TB/HIV Patients 
Although the definition of multimorbidity has been differing over the years, the 
AMS has defined multimorbidity as the coexistence of two or more chronic diseases or 
conditions (AMS, 2018). Patients with multimorbidity have an increased risk of 
premature death, high hospitalization, high costs of care, and low quality of life (AMS, 
2018; Violan et al., 2014). 
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The prevalence of multimorbidity is increasing in both developed and developing 
countries. Oni et al. (2015) showed that multimorbidity is high in TB/HIV patients in 
South Africa and indicating that NCDs are occurring alongside infectious diseases. HIV 
is known as comorbidity among TB patients. Patients with HIV usually have other 
coinfections in addition to TB, leading to multimorbidity. In TB/HIV patients, 
Multimorbidity is one of the factors postulated to lead to death among TB/HIV patients 
(Mchunu et al., 2016; Musaazi et al., 2018). The higher the number of comorbidities, the 
greater the chance of mortality (Lix et al., 2016). According to Nunes et al. (2016). 
Multimorbidity is associated with an increase in the risk of death mortality. However, 
Schäfer et al. (2018) indicated that the effect of multimorbidity on mortality is still 
disputed. Earlier studies by Haregu et al. (2012) showed that mortality may be associated 
with multimorbidity, gender, age, education status, income, and social, economic status. 
Determinants and Patterns of Multimorbidity 
There are well known determinants of multimorbidity that include age, gender, 
and low socioeconomic status. Multimorbidity has been associated with increasing age, 
although studies in Africa show that young age is also associated with multimorbidity 
(AMS, 2018; Oni et al., 2015). Females are highly associated with multimorbidity than 
males, as shown by Violan et al. (2014). However, studies in sub-Saharan Africa show a 
mixed picture where for some diseases, the prevalence is more in males than females 
while in others, it is more in females than males (Oni et al., 2015). The low socio-
economic status, as measured using the deprivation index, educational level, and health 
insurance coverage, is significantly associated with multimorbidity (Violan et al., 2014). 
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Usually, the patterns of multimorbidity are determined by the most prevalent 
conditions in a given geographical location. In European countries and the US, the typical 
multimorbidity patterns are hypertension and osteoarthritis or cardiometabolic conditions 
(Violan et al., 2014). In sub-Saharan Africa, it is becoming clear that there is a dual 
burden on non communicable and infectious diseases, and this constitutes the patterns of 
multimorbidity. Oni et al. (2015) observed the typical patterns of multimorbidity in South 
Africa included hypertension, diabetes, HIV, and TB. (Oni et al., 2015). The high 
prevalence of chronic and infectious diseases in sub-Saharan Africa confirms the ongoing 
epidemiological transition in the region and the need to reexamine the way 
multimorbidity are treated in primary health care centers (Oni et al., 2015) 
Measures of Multimorbidity 
There are various types of measuring multimorbidity. Haregu et al., (2012) 
indicated two conventional approaches to measuring multimorbidity, namely using a 
single condition and clustering of diseases into nonrandom group. According to Lefèvre 
et al. (2014), there are four types of measures of multimorbidity. The measure includes a 
simple count of chronic diseases. The second method is grouping diseases from a given 
list as dyads or triads; identifying common groups with the same diseases and 
characteristics, the third includes identifying an index disease first, and the fourth 
includes identifying homogenous groups of people with similar characteristics and 
similar diseases (Lefevre et al., 2014).  
According to Wallace et al., (2016), three standard comorbidity measures have 
been used in research to measure comorbidities. The measures include the following. (a) 
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count based morbidity measures involving a simple count of chronic diseases. (b) 
Charlson comorbidity index, based on a list of 17 conditions (Lix et al., 2016; Wallace, 
McDowell, Bennett, Fahey, & Smith, 2016). Each condition assigned a weight of 1 to 6, 
with zero indicating no comorbidity. (c) Other similar measures used to measure 
comorbidity are RXRisk comorbidity assessment, Elixhauser Comorbidity Index and 
Johns–Hopkins Adjusted Clinical Group® (ACG®), Chronic Disease Score, Number of 
Diagnoses and Number of Prescription Drugs Dispensed. The tools use data from patient 
charts or electronic medical records. Some authors had pointed out that although 
comorbid measurements have been around for some time, there was no validated tool for 
TB that measures health status or comorbidities (Brown et al., 2015). However, from the 
ongoing discourse, there are still varied ways of measuring multimorbidity based on 
different authors. Therefore, a careful review of the measurements and application would 
be prudent. 
Most of the multimorbidity studies have focused on the prevalence, patterns, and 
determinants of multimorbidity (Violan et al., 2014). The most common design for 
studies is the cross-sectional design (AMS, 2018; Oni et al., 2015). Patients in 
multimorbidity studies have been identified through self-reporting illness or extraction of 
data from electronic medical records. There are several methods used in multimorbidity 
studies, as indicated in the following paragraph. 
The patterns of multimorbidity in several studies have been analyzed using cluster 
analysis and factor analysis (Violan et al., 2014). While analyzing determinants like 
socioeconomic class, the studies have used odds ratios. The test used to test patterns 
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include λ2 to measure the difference in the prevalence of chronic disease and 
multimorbidity. The tests used to test for significance include the Shapiro-Wilk test used 
to test normality and the Kruskal Wallis test to test for significance of non parametric 
continuous variables. Significance testing was done in some studies using 2-sided p 
values and 95% confidence intervals. 
An increasing number of research on multimorbidity have been conducted since 
the 2000s (Oni et al., 2015; Van den Akker et al., 2001). Researchers described how 
research on multimorbidity should be conducted with a highlight the selection of the set 
of comorbid diseases to measure, and these should be the more prevalent diseases in a 
given study setting (Van den Akker et al., 2001; Cassell et al., 2018). The research on 
multimorbidity has focused on four primary areas the magnitude of multimorbidity 
(incidence and prevalence), the patterns which focus on the clustering of multimorbidity, 
the severity that focuses on frailty, and determinants of multimorbidity that include age, 
gender, and socioeconomic status (Oni et al., 2015; Weimann et al., 2016). 
 The approach used broadly to investigate these issues is the quantitative 
approach. The quantitative approach has three broad areas that include data collection, 
data analysis, and interpretation. Data collection for multimorbidity has been done either 
through self-report, interview questionnaires, or data extraction from existing databases 
(Casell et al., 2018). The following methods are used in data analysis, counts, analysis 
using multiple regression, stratified analysis according to Mantel Haenzel, or stepwise 
multiple logistic regression (Van den Akker et al., 2001). Also, relative risk or odds ratio, 
confounding variables like age, socioeconomic status, environmental factors, and 
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psychological factors should be taken care of as confounders and effect modifiers (Van 
den Akker et al., 2001).  
In recent research, researchers have mostly used retrospective cross-sectional 
designs to explore comorbidities (Casell et al., 2018; Creswell et al., 2011; Oni et al., 
2015; Pepper et al., 2015). There are some strengths in using retrospective cross-sectional 
designs. The use of retrospective cross-sectional designs may be attributed to the fact that 
prospective designs take a long time, and an instant study would have limited data. 
Therefore, retrospective designs are used because they are quick to perform as compared 
to prospective studies. In multimorbidity studies, researchers usually require large sample 
sizes that are difficult to obtain with prospective studies within a short period. The 
retrospective cross-sectional studies have the advantage of collecting large volumes of 
data in a short time (Casell et al., 2018; Weimann et al., 2018). Also, retrospective studies 
require a lower cost as compared to prospective studies. Usually, the costs of prospective 
designs as compared to retrospective designs are high and inhibitive (Creswell et al., 
2011). 
Although retrospective studies have been used to examine multimorbidity, they 
have inherent weaknesses like a lack of variables that may be useful to consider (Umanah 
et al., 2015). Retrospective designs usually depend on already collected data from 
medical records and may collect all the relevant variables, including confounders 
(Umanah et al., 2015; Weimann et al.; 2016). However, some previous studies extracting 
data from electronic registers may have lacked variables like CD4 cells, date of initiation 
of treatment because these were missing in those databases (Oni et al., 2015). In this 
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study, because of the limitations of time and cost of the survey, I used retrospective 
cohort records to review the design with the quantitative design. In the past, 
multimorbidity has been defined in various ways, and therefore, it was difficult to 
compare studies. After 2018, the AMS (2018) has defined multimorbidity to mean the 
coexistence of two or more chronic conditions of long duration physical non 
communicable disease, mental condition on infectious disease (AMS, 2018). The new 
definition means that the comparison of studies would no longer be a limitation to 
multimorbidity studies. 
Justification of Selected Variables or Concepts 
The selection of independent and dependent variables was based on gaps 
observed in the existing literature of the variables as elaborated in the conceptual 
framework and the literature reviewed on multimorbidity (Oni et al., 2015; Weimann, et 
al., 2016). Also, the variables were best on the best predictors of outcomes based on 
previous literature. 
The independent variables are multimorbidity, and a group of multimorbidity was 
selected: diabetes mellitus, hypertension, malnutrition, pneumonia, cancers. The author 
based the multimorbidity selection on the frequent multimorbidities documented in TB 
patients in sub-Saharan Africa and Uganda (Oni et al., 2015; WHO, 2018). The 
dependent variable is mortality. This variable was selected because mortality is 
associated with multimorbidity. However, there is no study for TB/HIV that has 
associated mortality with multimorbidity (Mchunu et al., 2016). This study is likely to 
give insights into the association between mortality and multimorbidity. Covariables for 
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this study selected include age, gender, income, education, marital status, and social, 
economic status (Mchunu et al., 2016; Pepper et al., 2015). These covariables are always 
included in other studies of multimorbidity (AMS, 2018). Most multimorbidity is 
attributed to gender, age, and low socioeconomic class. (Violan et al., 2014). The next 
section comprises the literature on each of the variables. Independent variables included 
multimorbidity, age, sex, marital status, phase of TB treatment, the timing of ART 
initiation, and type of TB. The dependent variable was mortality.  
This section describes the literature for all the study variables that are within the 
last 5 years. However, important literature that goes beyond 5years is also included. The 
literature covers, what is known, the gap, and what this study may contribute to the 
existing body of knowledge for TB/HIV patients on ART. The variables of the study 
include mortality, which is a dependent variable. The rest of the variables are 
independent variables. They include multimorbidity, demographic factors (sex, age, and 
marital status), the phase of TB treatment (Initiation and continuation), the time of 
initiation of ART, and the type of TB. 
Mortality Among TB/HIV Patients on ART 
An increasing number of researches on mortality have been conducted since the 
2000s (Mchunu, et al., 2016; Oni et al., 2015;). The research on TB/HIV mortality has 
focused on TB/HIV patients in general and not necessarily on ART alone, socio-
demographics clinical and immunological information as independent variables, and 
mortality as the dependent variable (Mchunu et al., 2016; Musaazi et al., 2019; Stijnberg 
et al., 2019; Tola et al., 2019;). The primary outcomes of these study show that ART is 
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protective for TB patients, and death is usually associated with patients who are not on 
ART, with adverse effects, and who begin ART late variable (Mchunu et al., 2016; 
Musaazi et al., 2019; Stijnberg et al., 2019; Tola et al., 2019;).  
The initiation of ART among TB/HIV patients led to the improvement of 
treatment outcomes. However, despite ART initiation among TB/HIV patients, the 
mortality among these patients is high (Mchunu et al., 2016; Musaazi et al., 2019; WHO, 
2018). In Swaziland, the evaluation of the 2010 – 2013 cohort showed similar findings 
where about 13% of TB/HIV coinfected patients were dying despite ART (Mchunu et al., 
2016). Similar findings have also been found in Uganda by Musaazi et al. (2019), where 
about 10% of TB/HIV coinfection are still dying. However, in all the studies, the risk 
factors associated with the high case fatality rates are not well known. 
Mortality as a Dependent Variable 
Mortality has been indicated as an outcome of multimorbidity (AMS, 2018; Smith 
et al., 2017). Multimorbidity has worse consequences, including mortality, disability, 
institutionalization, greater use of health care, miserable quality o life, and high side 
effects (Vetrano et al., 2017). Mortality in TB/HIV coinfected patients remains high 
globally despite the implementation of the test and treat policy for ART among TB/HIV 
patients. The link between mortality and multimorbidity among TB/HIV patients is not 
well understood. I explored the link between multimorbidity, health care processes, and 
mortality among TB/HIV patients on ART. One of the studies conducted in Denmark 
showed high death among people with multimorbidity was male, single or unmarried, 
low income status, and high age of 60 to 70 years (Taleshan et al., 2018).  
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Multimorbidity Among TB/HIV Patients 
Although the definition of multimorbidity has been differing over the years, the 
AMS (2018) defines multimorbidity as the coexistence of two or more chronic diseases 
or conditions (AMS, 2018). Patients with multimorbidity have an increased risk of 
premature death, high hospitalization, high costs of care, and low quality of life (AMS, 
2018; Violan et al., 2014). According to Nunes et al. (2016), multimorbidity is associated 
with an increase in the risk of mortality. However, Schäfer et al. (2018) indicate that the 
effect of multimorbidity on mortality is still disputed. The prevalence of multimorbidity 
is increasing in both developed and developing countries. Oni et al. (2015) showed that 
multimorbidity is high in TB/HIV patients in South Africa and indicating that NCDs are 
occurring alongside infectious diseases. HIV is known as comorbidity among TB 
patients. Patients with HIV usually have other coinfections in addition to TB, leading to 
multimorbidity. In TB/HIV patients, multimorbidity is one of the factors postulated to 
lead to death among TB/HIV patients (Mchunu et al., 2016; Musaazi et al., 2018). The 
higher the number of multimorbidities, the greater the chance of mortality (Lix et al., 
2016). The gap in this study is that there is little literature that multimorbidity is 
associated with mortality among TB/HIV patients on ART (Mchunu et al., 2016; Musaazi 
et al., 2019; Stijnberg et al., 2019; Tola et al., 2019;). In this study, I determined the 
association between multimorbidity (non communicable disease clusters like diabetes, 




Several patterns of multimorbidity exist in different parts of the world. In Europe 
and the USA, several studies indicated the most common multimorbidity patterns. The 
most common multimorbidity patterns were cardiometabolic and cardiovascular. Others 
included metabolic, cardiorespiratory pattern, metabolic pattern, neuropsychiatric, and 
musculoskeletal (Vetrano et al., 2017; Violan et al., 2014). In developing countries where 
both infectious and non communicable diseases exist the especially in sub-Saharan 
Africa, because of the ongoing epidemiological transition, the multimorbidity pattern was 
mixed with hypertension, diabetes, HIV, and TB (Oni et al., 2015). For this study, which 
was conducted in Uganda found in sub-Saharan Africa, the independent variables were 
multimorbidity, age, sex, marital status, phase of TB treatment, the timing of ART 
initiation, and type of TB, while the dependent variable is mortality (Mchunu et al., 2016; 
Pepper et al., 2015). The following sections describe the essential constructs and 
variables that were used in this study. 
Diabetes Mellitus 
Globally, the prevalence of diabetes is increasing, and patients with diabetes are at 
higher risk of multimorbidity. Patients with diabetes are at increased risk of 
cardiovascular, cerebrovascular diseases, pulmonary TB, kidney disease, dementia, and 
depression leading to premature illness and death (Chen et al., 2016). In countries with 
limited resources, the incidence of TB is declining while the number of notified cases of 
diabetes mellitus is rising, giving rise to a double burden (Bates et al.,2015; Kapur & 
Harries, 2013; Reis-Santos et al., 2013; Ugarte-Gil & Moore, 2014). The WHO studies 
reveal that diabetes is the second common comorbidity after HIV in patients with TB 
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(WHO, 2015). There could be variations by country based on the prevalence of TB; high 
TB burden countries are likely to have HIV as comorbidity, while in those countries 
where the HIV prevalence is low, diabetes is likely to be the most prevalent comorbidity, 
especially in populations above 65 years (Brown et al., 2015). In Asia, Ko et al. (2016) 
found that the prevalence of TB among TB patients had increased by 27% over the 10 
years 2000 to 2010 (Ko et al., 2016). To manage the TB and diabetes comorbidity, WHO 
has created a framework similar to the TB/HIV framework (Sharma et al., 2014). The 
primary objectives are, establish mechanisms for collaboration, detect and manage TB in 
patients with diabetes, and identify and manage diabetes in patients with TB. Also, a 
monitoring framework has been developed to ensure surveillance (Bates et al., 2015). 
Brown et al. (2015) explained the misdistribution of fat (lipodystrophy) in HIV patients 
on non nucleoside reverse transcriptase inhibitors in patients with diabetes, 
hyperglycemia, and obesity are some of the comorbidities that manifest in the HIV 
patients on ART. (Brown et al., 2015). Higher mortality is observed in patients with more 
types of comorbidities (Oni et al., 2015). 
Hypertension 
TB and cardiovascular diseases have been noted to have links, although 
cardiovascular conditions are not direct risk factors for TB (Creswell et al., 2011). The 
effects of TB on the lungs have been known to give rise to pulmonary hypertension 
(Creswell et al., 2011). In studies conducted in South Africa, hypertension was found to 
be the most prevalent comorbidity in both diabetic and HIV patients (Oni et al., 2015; 
Weimann et al., 2016). The most common comorbidity among TB patients was 
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HIV/ART, followed by hypertension and diabetes (Oni et al., 2015; Weimann et al., 
2016). The epidemiological transition is eminent in low-resource settings, where more 
non communicable diseases, including hypertension, are becoming prevalent with an 
equally high burden of communicable or infectious diseases (Creswell, 2011; Weimann 
et al., 2016). The dual burden of infectious and non infectious diseases may indicate the 
need to conduct more studies. Such e studies should explore the links of hypertension 
with TB focusing on high TB burden settings (Weimann et al., 2016). 
Malnutrition 
Malnutrition is associated with mortality in patients with multimorbidity, 
contributing to 10-85% of patients with multimorbidity. Mini nutritional assessment may 
be an easier way of measuring nutritional status in patients with multimorbidity. Usually, 
there are 18 items, but these are reduced to 7, including weight loss, mobility, body mass 
index, number of full meals, mode of feeding, fluid consumption, and health status. The 
new indices are 12.5–15 represents well-nourished, 9–12 represents those at risk of 
malnutrition, and less than nine those who are malnourished. 
Pneumonia 
Pneumonia is one of the comorbid diseases found in patients with multimorbidity, 
especially the elderly. The elderly with multimorbidity have pneumonia called 
community-acquired pneumonia. The risk of pneumonia is high in frail elderly 
hospitalized patients. The most frequent type of pneumonia that affects the adult is 
Streptococcus pneumonia. About 45% of all the cases of community-acquired pneumonia 
occur in the elderly above 65 years. To avoid pneumonia in the elderly, issues around 
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lifestyle, including immunization in the elderly, have to be considered. Mortality due to 
pneumonia in the elderly is 25% higher than in the general population. 
Cancers and Mental Health 
Cancers increases with age, and the increase in age is associated with 
multimorbidity. In patients above 65 years, more cancers and other multimorbid diseases 
are usually common (AMS, 2018). However, there are few studies on cancers and 
multimorbidity. Taking care of multimorbidity in cancer patients could be crucial since 
multimorbidity increases in patients with cancer and risk factors such as smoking, 
obesity, and alcohol use (AMS, 2018). The common multimorbidity includes myocardial 
infarction, osteoporosis, stroke, and metabolic syndrome. Mortality, quality of care, and 
treatment complications need to be taken care of in such cancer patients. Multimorbidity 
is associated with mental health. People with mental health have a 25-year life 
expectancy less than the other individuals. Mental health can be measured using 
depression (AMS, 2018). There is a detailed questionnaire that has been developed over 
time used to assess mental health. 
Age, Gender, and Socioeconomic Status and Mortality 
There are well known determinants of mortality that include age, gender, and low 
socioeconomic status. Earlier studies by Haregu et al. (2012) showed that mortality may 
be associated with gender, age, education status, income, and social, economic status . 
Mortality has been associated with increasing age, although studies in Africa show that 
young age is also associated with mortality in TB/HIV patients (AMS, 2018; Oni et al., 
2015). Females are highly associated with mortality than males, as shown by Violan et al. 
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(2014). However, studies in sub-Saharan Africa show a reversed picture where males die 
more than females in TB/HIV patients (Oni et al., 2015). The low socioeconomic status, 
as measured using the deprivation index, educational level, and health insurance 
coverage, is significantly associated with mortality (Violan et al., 2014). The current gap 
is that there is little evidence in sub-Saharan Africa about the association of mortality 
with age, mortality, and marital status among TB/HIV patients on ART (Mchunu et al., 
2016; Musaazi et al., 2019; Stijnberg et al., 2019; Tola et al., 2019;). In this study, I 
analyzed the association between demographic factors (sex, age, and marital status) and 
mortality among TB/HIV patients on ART. 
TB Treatment Phase and Mortality  
Patients diagnosed with susceptible TB take treatment for 6 months during the 
initial phase and continuation phase. The initial phase of TB treatment consists of 2 
months of treatment. The initial phase has 4medicines: a fixed dose of rifampicin, 
isoniazid, pyrazinamide, and ethambutol (WHO, 2018). The combination of medicines 
kills the tubercle bacilli rapidly, and the patient becomes non infectious in about 2 weeks, 
and symptoms subside (WHO, 2013). PBC patients rapidly become sputum negative by 
the end of 2 months. These medicines are highly effective in HIV and non-HIV patients 
who may harbor a sizeable bacillary load. The continuation phase is given for 4 months 
with rifampicin and Isoniazid (WHO, 2018). Studies indicated that mortality is high in 
patients in the initial phase, especially at 2 months (Musaazi et al., 2019; Stijnberg et al., 
2019; Tola et al., 2019;). However, these studies do not necessarily comment on the 
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initial or continuation phase (Mchunu et al., 2016; Musaazi et al., 2019; Tola et al., 
2019). 
Most of these studies point out that these patients with high mortality at 2 months 
may not be on ART. Mortality at 2 months may also be due to delayed diagnosis and the 
start of TB treatment (Stijnberg et al., 2019; Tola et al., 2019;). This finding indicates a 
gap in the knowledge of what happens in the era of ART, test, and treat policy. Are 
patients still dying at 2 months in the initial phase, or are they dying in the continuation 
phase? There is a need to explore when mortality happens in patients initiated on ART 
and then develop TB, and even those who begin ART after TB treatment. This study 
analyzed the association between TB treatment (Initiation and continuation phase) and 
mortality among TB/HIV patients on ART. The phase of TB treatment was the 
independent variable, while mortality was the dependent variable, and all these were 
categorical variables. Also, the analysis indicates those who died either in the initial or 
continuation phase and when they started ART. 
Time of initiation of ART and Mortality Among TB/HIV Patients 
Delay in ART initiation is one of the associations of mortality in TB/HIV patients, 
yet accelerated ART initiation improves clinical outcomes (Ford et al., 2018; Lisboa et 
al., 2019). Some earlier studies had shown that health workers could delay ART in those 
with less risk of IRIS and adverse reactions (Tola et al., 2019; Lisboa et al., 2019). 
However, in those studies, ART was only indicated in patients with a CD4 cell count of 
less than 200. However, mortality has continued to be high among patients with TB/HIV 
on ART (Gatechompol et al., 2019; Musaazi et al., 2019; WHO, 2018). During 2012, the 
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recommendation of when to start ART in TB/HIV patients became very important 
(Gatechompol et al., 2019). 
 In 2013, WHO produced a test and treat policy, and for all TB/HIV patients, 
ART was to begin within 8 weeks of the TB patients beginning TB treatment 
(Gatechompol et al., 2019). On the other hand, patients who have HIV and are on ART 
can still develop TB. However, no known studies were found which indicate the 
association between time of initiation of ART (before the start of TB treatment and after 
the start of TB treatment) and mortality among TB/HIV patients on ART, and this is a 
gap. This study was used to determine the association between time of initiation of ART, 
before the start of TB treatment and after the start of TB treatment, and mortality among 
TB/HIV patients on ART. The results could contribute to the body of knowledge of the 
time of initiation of ART and mortality. 
Type of TB and Mortality Among TB/HIV Patients 
TB is either extrapulmonary or pulmonary TB (WHO, 2019). Most of the patients 
with TB are usually pulmonary. The pulmonary TB patients are either pulmonary 
bacteriologically confirmed (PBC) or pulmonary clinically diagnosed (PCD). The 
pulmonary bacteriologically confirmed that people with TB include diagnosis using 
microscopy GeneXpert, culture, and other molecular tests. The diagnosis of a pulmonary 
clinically diagnosed patient is based on the appearance of radiological abnormalities 
suggestive of TB. The patient is usually bacteriologically negative. Also, the PCD 
diagnosis can be made based on the judgment of a health worker who decides to start 
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treatment with a high suspicion of TB. High mortality among TB/HIV patients was 
usually associated with PCD and extrapulmonary TB (Lisboa et al., 2019; WHO, 2006).  
Mortality in EPTB and PCD is associated with the delay in diagnosis and delay in 
treatment of TB (Lisboa et al., 2019). However, the findings are now mixed, with some 
studies showing an association of high mortality with PBC, PCD, and EPTB, while other 
studies show the contrary (Lisboa et al., 2019; Tola et al., 2019). A significant number of 
these studies were conducted when ART was only recommended in patients with a CD4 
cell count of less than 200 (Lisboa et al., 2019; Stijnberg et al., 2019: Tola et al., 2019). 
The current literature gap points out inadequate information about the type of TB and its 
association among TB/HIV patients on ART during the test and treats all TB/HIV 
patients on ART (Tola et al., 2019). This study examined the association of type of TB 
with mortality among TB/HIV patients on ART. The study provided new information to 
add to the body of existing knowledge for TB/HIV associated mortality.  
Summary and Conclusions 
Uganda is a high TB/HIV country among the 30 high burden TB/HIV countries in 
the world with poor TB treatment outcomes (WHO, 2018). The country still records high 
mortality of about 13% among TB/HIV coinfected patients on ART despite the high ART 
coverage (MoH, 2018; Musaazi et al., 2019; WHO (2018). The current studies on 
multimorbidity show that mortality is a core outcome of multimorbidity. The studies also 
highlight the fact that there is inadequate literature on multimorbidity in middle- and low-
income countries (Catala-Lopez et al., 2018; Smith et al., 2018; Xu, Mishra, & Jones, 
2017). The studies reviewed on TB/HIV had inadequate information on the association of 
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multimorbidity and mortality among TB/HIV coinfected patients on ART (Mchunu et al., 
2016; Oni et al., 2015; Pepper et al., 2015). 
In studies conducted globally by Bates et al. (2015) and WHO (2018) indicate that 
multimorbidity could be contributing to the mortality among TB/HV patients. Oni et al. 
(2015) and Peltzer (2018) suggest that comorbidity or mortality could be associated with 
mortality among TB/HIV patients in South Africa. Studies conducted in Uganda show 
that high mortality among TB/HIV may be associated with several factors. The factors 
include extrapulmonary TB, low CD4 cell count, late presentation, several comorbidities, 
low Karnofsky score (Kirenga et al., 2014, Musaazi et al., 2019). All the studies reviewed 
indicate that multimorbidity among TB/HIV patients may be associated with mortality. 
However, none of these studies shows any statistical significance that comorbidity or 
multimorbidity contributes to mortality among TB/HIV patients on ART (Bates et al., 
2015: Kirenga et al., 2014; Musaazi et al., 2019; Oni et al., 2015). The preliminary 
finding highlights the need for research on the association between mortality and 
multimorbidity among TB/HIV patients on ART in Uganda.  
The purpose of the study was to test and analyze the association between 
multimorbidity, health care processes, and death among TB/HIV patients on ART. One 
of the independent variables is multimorbidity. In this study, a patient has multimorbidity 
if they have any two diseases in addition to TB and HIV. Examples of these diseases are 
diabetes mellitus, hypertension, malnutrition, pneumonia, cancers. Multimorbidity was 
measured as yes or no. The other independent variables include demographic factors 
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(age, sex, and marital status), phase of TB treatment time of initiation of ART. The 
dependent variable is mortality. 
In this study, the health outcomes conceptual framework has been used. The 
framework has four domains: health care system, patient characteristics, care or 
interventions, and outcomes, and has components derived from the Donabedian model of 
quality improvement. (Canadian Institute for Health Information, 2008; Sbarigia et al., 
2016). In the past, multimorbidity in TB was measured using TB non specific tools. The 
tools used are the counting method, SF-36, Charleson comorbidity index, among others. 
However, new tools specific to measuring multimorbidity in TB like FACIT –TB are 
now available and should be utilized and refined.  
Worldwide a significant proportion of TB/HIV patients has been started on ART. 
However, many of them still die; this highlights the gap that warrants further 
investigation, mainly focusing on multimorbidity as one of the likely causes of the 
associated mortality. This study could fill the literature gap by the author testing the 
association between multimorbidity and mortality among TB/HIV patients on ART and 
make recommendations that can be taken up by the policymakers and practitioners. The 
literature review would guide the next chapter on research methods, including the 
research design and rationale, the methodology, sampling and sampling procedures, 




Chapter 3: Research Method 
Introduction 
TB/HIV coinfected patients are initiated on life saving ART. However, mortality 
has remained high among TB/HIV patients globally and in sub-Saharan Africa (Mchunu 
et al., 2016; Oni et al., 2015; Pepper et al., 2015; WHO, 2018). There is inadequate 
information about multimorbidity in middle-income and lower-income countries, 
including Uganda (Catala-Lopez et al., 2018). As stated in Chapter 1, the purpose of this 
quantitative study was to test and analyze the association between multimorbidity, health 
care processes, and mortality among TB/HIV patients on ART in Uganda. The major 
sections of this chapter include research design and rationale, the methodology, sampling 
and sampling procedures, procedures for recruitment, participation, data collection for 
secondary data, instrumentation and operationalization of constructs, data analysis plan, 
threats to validity, and ethical procedures. This chapter concludes with an overall 
summary of the research methods. 
Research Design and Rationale 
In this study, the independent variables were multimorbidity, age, sex, marital 
status, phase of TB treatment, initiation of ART after the start of TB treatment, and type 
of TB. Multimorbidity included diabetes, hypertension, malnutrition, cancers, and other 
multimorbidities. These multimorbidities were selected based on their occurrence in sub-
Saharan Africa, as indicated in the literature review (Oni et al., 2016; Peltzer, 2018). The 
dependent variable was mortality. I used a quantitative cross-sectional design with a 
review of medical records. The medical records have data elements for TB and HIV 
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patients in all hospitals and some health centers in Uganda. The records are collected 
during the clinical review of patients by hospital staff. The HIV data are first collected on 
the patient ART card and later entered into electronic medical records. TB patients’ data 
are entered into the Unit TB register after a patient is diagnosed with TB and initiated on 
treatment. The following are the research questions studied using the cross-sectional 
design and review of records: 
RQ1: What is the association between multimorbidity (disease clusters) and 
mortality among TB/HIV patients on ART? 
RQ2: What is the association between demographic factors (sex, age, and marital 
status) and mortality among TB/HIV patients on ART? 
RQ3: What is the association between the phase of TB treatment (initiation and 
continuation) and mortality among TB/HIV patients on ART? 
RQ4: What is the association between time of initiation of ART (before the start 
of TB treatment and after the start of TB treatment) and mortality among TB/HIV 
patients on ART? 
RQ5: What is the association between type of TB (pulmonary bacteriologically 
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality among 
TB/HIV patients on ART? 
The constraints associated with the cross-sectional design and review of records 
are varied and include missing data elements. This constraint is compensated for by using 
large volumes of data and eliminating the data with missing variables. Usually, accessing 
secondary data that needs extraction is cumbersome because it needs approvals at many 
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levels. However, this challenge was sorted out by ensuring the MoH issued a letter of 
introduction to the regional referral hospitals. The letter identified the request for the data 
for research.  
The cross-sectional design, coupled with a secondary review of the medical 
records, ensured easy access to large volumes of data collected over a long period. The 
costs to collect primary data were saved. Also, it is ethical to use the existing secondary 
data instead of trying to collect primary data from patients affecting their physical or 
mental well-being (Laureate, 2012). Over the last two decades, multimorbidity data have 
been collected through either interview of patients or review of medical records. For 
example, recent multimorbidity studies by Peltzer (2018), Weimann et al. (2016), Oni et 
al. (2015), and Pepper et al. (2015) were conducted using cross-sectional designs and 
reviews of records. Cross-sectional studies are known for describing variables and 
distribution of patterns and examining associations between predictors and outcomes 
(Hulley, 2007). Cross-sectional studies and reviews of records have been used to build 
the body of existing knowledge on multimorbidity and therefore were suitable for this 
study (AMS, 2018; Rudestram & Newton, 2015). 
Methodology 
Population, Sampling, and Sampling Procedures 
The target population of this study was TB/HIV patients on ART in Uganda. In a 
year, about 17,000 TB/HIV patients are notified in Uganda (WHO, 2016). For this study, 
the accessible population was the TB/HIV patients on ART in the Unit TB register and 
ART cards or HIV electronic medical records at the national and regional referral 
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hospitals in Uganda. The intended sample of the study was TB/HIV patients enrolled on 
ART in selected hospitals in Uganda. The patients were registered in TB and ART cards 
or HIV electronic medical records in Uganda between January 2017 and December 2019. 
Systematic sampling was conducted to reach the intended number of regional hospitals. 
Nine out of the 14 regional referral hospitals with the corresponding sample size of 
available patients were selected. Data for TB/HIV patients on ART were extracted for all 
TB/HIV adults and children from January 2017 to December 2019 from the selected nine 
hospitals.  
Inclusion and Exclusion Criteria 
The sampling included TB/HIV patients on ART in selected regional referral 
hospitals registered in the Unit TB registers and ART client cards between 2017 and 
2019. All TB/HIV patients on ART were included in the sample. The data were 
abstracted from the TB registers and ART cards for 2017–2019 for all TB/HIV patients. 
For TB/HIV patients whose records were missing some vital data, elements were 
excluded from the study. The patients who did not meet the criteria were excluded from 
the study. 
Using Power Analysis to Determine Sample Size  
I used G Power Version 3.1.9.2 to determine the minimum sample size for logistic 
regression for a dichotomous predictor, a significant predictor of a binary outcome 
(mortality), with or without other covariates (Faul et al., 2009). The following 
information, including statistical power, alpha, and effect size, was used. Usually, the 
statistical power of 80% (0.8) is recommended to test a relationship between the 
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independent and dependent variables. For alpha, I used a predetermined figure of 0.05 to 
maintain the high power of the study. Pr (Y = 1 | X = 1) H1, and I assumed the 
probability of mortality for TB/HIV patients on ART with multimorbidity is H1 = 0.18. 
Then Pr (Y = 1 | X = 1) H0 = the probability of mortality (Y = 1) when someone has no 
multimorbidities. If the probability of mortality for patients without multimorbidity is H0 
= 0.09 (TB patients without HIV), the two probabilities give an odds ratio of 2.524. Then 
R squared (R2 other X) = the expected squared multiple correlation coefficient (R 
squared) between the main categorical predictor (multimorbidity status) and all other 
covariates. R squared represents the amount of variability in the main predictor 
(multimorbidity) that is accounted for by the covariates. X param π = The proportion of 
multimorbidity cases and are dead; this is estimated at 0.5. The sample size was 2,405. 
Assuming 20% (481) of the data were missing variables, the sample size would be 
adjusted to compensate for the missing variables. The new sample size was adjusted to 
2,886, representing 62,362 TB/HIV patients on ART in Uganda from 2017–2019. Table 1 
shows the output of the G Power.  
Table 1 
 
Calculation of Sample Size using G Power 
No. Parameter Result 
1 Tails 2 
2 Pr(Y=1/X=1) H1 0.18 
3 Pr(Y=1/X=1) H0 0.09 
4 Alpha 0.05 
5 R2 other X 0.81 
6 X distribution binomial 
7 X Parm π 0.5 
8 Critical z 1.9596640 




Archival Data/Secondary Data 
Recruitment, Participation, and Data Collection  
In the study, I used existing secondary data at the regional referral hospitals as 
medical records for TB and HIV patients. These secondary data were from the Unit TB 
register and ART cards. The primary data are usually collected during routine evaluations 
of TB and HIV patients; a clinician enters the data on the ART card or Unit TB registers. 
The Unit TB register has the following variables: (a) name and contact of the person, (b) 
health worker, (c) age, (d) sex, and (e) address (district, county, subcounty, parish, 
village). There is a column for disease classification—in this case, type of TB. Pulmonary 
bacteriologically confirmed (PBC) TB occurs in the lungs and is identified through smear 
microscopy or molecular technology. Pulmonary clinically diagnosed (PCD) TB occurs 
in the lungs but cannot be identified through smear microscopy or molecular technology. 
Extrapulmonary (EP) TB occurs outside the lungs. There is also a column for the type of 
patient (new, relapse, failure; loss to follow up; treatment history unknown); date 
treatment started and regimen, transfer in, results of sputum and other results, TB/HIV 
activities (CT, HIV result, CPT, ART) IPT, treatment model (community or facility), 
issue of anti-TB drugs (intensive/continuation phase), treatment outcome (cured, 
completed, failure, died, transferred out, loss to follow up, diagnosed with DR–TB). 
Among the data elements listed, a few data elements were collected from the Unit TB 
registers at the regional referral hospitals. The data on independent variables and the 




The selection of independent and dependent variables for this study was based on 
gaps observed in the existing literature of the variables as elaborated in the conceptual 
framework and the literature reviewed on multimorbidity (Oni et al., 2015; Weimann et 
al., 2016). Also, the variables of the best predictors of outcomes were based on previous 
literature. In the section below, I describe all the variables. The variables include 
measurement, type of variable, and the tool used to extract it. 
Dependent Variables  




The dependent variable, measure, type, and tool 
Dependent variable  Measurement Type of variable Tools to use 
Mortality Yes/No  Categorical/nominal Data retrieval form 
 
Independent Variables  
The independent variables are multimorbidity, age, sex, marital status phase of 
TB treatment, initiation of ART after the start of TB treatment, and type of TB. 
Multimorbidity includes diabetes, hypertension, malnutrition, cancers, asthma, peptic 
ulcer disease, and others. The different multimorbidities were selected based on their 
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Additional data were extracted from the ART cards of TB/HIV patients on ART. 
The presence of multimorbidity was recorded as Yes, and recorded in the column labeled, 
“other medications dispensed,” including nutritional supplements (Peltzer, 2018). This 
data on medicines were used to come up with the most frequent chronic diseases in 
TB/HIV patients, namely, diabetes mellitus, hypertension, malnutrition, pneumonia, 
cancers, and others (Putnam et al., 2002). An expert physician provided the commonly 
prescribed medicines in Uganda for selected chronic diseases, and this was triangulated 
with the same chronic disease medical prescriptions in Uganda’s clinical guidelines. The 






Examples of some chronic diseases and their treatment 
Chronic 
disease 











Hypertension propranolol, captopril, 
nifedipine, atenolol, lisinopril, 




























Cancers Methotrexate, actinomycin D; 
cyclophosphamide, 
Vincristine, Vinblastine, 













Using a letter from the MoH, permission was sought from regional referral 
hospitals to access TB/HIV data from the clinics. The formal request for data use is a 
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standard procedure set by the MoH to gain access to the data from health facilities in the 
country. Several types of research have been conducted in regional referral hospitals. The 
practice has been to usually access this data without restrictions once the letter seeking 
authorization is presented. Once permission was granted, data was accessed from the Unit 
TB register and ART card. The data accessed was de-identified. 
The Unit TB register and ART card are the best sources of TB/HIV data. These 
are the tools where patient data is recorded daily when patients are attended to TB clinics 
and ART clinics. The medical health workers usually clerk, examine, investigate, 
diagnose, prescribe medicines, and conduct health education. The results from the 
medical processes are written in the Unit TB register and the ART card. The TB/HIV 
data is cheap to collect since it can be located easily in the clinics at the regional referral 
hospitals. The TB/HIV data from the ART card can also be accessed from the electronic 
medical record system in the regional referral hospitals, and this is a quick and easy to 
access process.  
Operationalization of the Variables 
This section highlights the operational definitions of both the independent and 
dependent variables. The section includes how each variable was measured. The section 
also includes how the scale or core was calculated. An example of how each item was 
measured and calculated is illustrated. 
Definitions of Independent Variables 
• Multimorbidity: Existence of more than one medical condition or situation an 
individual other than TB/HIV (AMS, 2018). 
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• Age: Period from the date of birth and time of when the patient had TB/HIV 
coinfection. 
• Sex: A differentiation between male and female. 
• Marital status: This is a legally defined marital state. It can be married, widowed, 
divorced, separated, or none.  
• The phase of TB treatment: The phase can be the initiation phase or continuation 
phase. The initiation (intensive) phase is 2 months and consists of four drugs: 
rifampicin, isoniazid, pyrazinamide, and ethambutol. The initiation phase regimen 
kills rapidly multiplying bacteria or semi dormant bacteria (WHO, 2014). The 
continuation phase is 4 months and consists of two drugs: rifampicin and 
isoniazid. The continuation phase regimen eliminates bacteria and reduces failure 
and relapse (WHO, 2014). 
• The timing of initiation for ART: This is whether the patient started antiretroviral 
treatment either before TB treatment or after the start of TB treatment.  
• Type of TB: TB is either extrapulmonary or pulmonary. The pulmonary TB is 
either pulmonary bacteriologically confirmed (PBC) or pulmonary clinically 
diagnosed (PCD). 
Nature of Scales 
For independent variables, the natures of scales are indicated in the paragraph 
below. All the independent variables were categorical except age; they include 
multimorbidity, sex, marital status, phase of TB treatment, initiation of ART before or 
after the start of TB treatment, and type of TB. The following independent variables were 
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collected from the secondary data source, the Unit TB register, ART cards, patient files, 
or electronic medical records. They were recorded as dichotomous variables as follows. 
• Multimorbidity: No multimorbidity = 1 and the presence of multimorbidity = 0 
• The different multimorbidities were further categorized and coded as follows: No 
multimorbidity = 0; Cancer =1, Cardiovascular =2, Dermatological =3, Endocrine 
=3, ENT =4, GIT =5, Hematological =6, Immunological =7, Infectious =8, Liver 
=9, Lymphatic =10, Musculoskeletal =11, Neurological =12, Nutritition =13 , 
Reproductive =14, Respiratory =15, Psychological = 16 
• Age was recorded as a continuous variable 0,1, 2,3,4 --------95 years 
• Sex was recorded as a dichotomous variable male = 0 and female = 1 
• Marital status was recorded as a categorical variable, married = 0, Widowed = 1, 
Divorced/separated = 2, Single = 3, Child =4  
• Phase of TB treatment, Initial phase =0, continuation = 2 and alive =3 
• Initiation of ART after the start of TB treatment Before or with TB treatment =0, 
after TB treatment = 1, 
• Type of TB, Pulmonary bacteriologically confirmed (PBC) =0, Pulmonary 
clinically diagnosed (PCD) =1, Extra pulmonary tuberculosis (EP TB) =2 
Data Analysis Plan 
SPSS Software, Data Collection, and Research Questions and Hypotheses 
The statistical package for the social sciences (SPSS) for Windows Version 25 
was used to analyze data. Data of the Unit TB register and electronic medical records 
from the regional referral hospitals were retrieved into a data retrieval form. A copy of 
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the data retrieval form and codebook are included in the appendix. The data collected in 
the retrieval forms were cleaned and maintained in an excel file as codes and then 
exported to SPPS; and analyzed. I checked the database for missing data, outliers, and 
inconsistencies. In case of such inconsistencies, original documents were checked and 
corrected. An audit log for all data changes was maintained. Priority for data cleaning and 
editing was given, especially for the dependent variables, to ensure no data is missing. 
Editing procedures were repeated to ensure all errors and missing variables are corrected, 
and the database was declared final and locked. 
Research Questions and Hypotheses 
The following are research questions with corresponding null and alternative  
hypotheses as written in chapter 1: 
RQ1: What is the association between multimorbidity (disease clusters) and 
mortality among TB/HIV patients on ART? 
H01: There is no association between multimorbidity (disease clusters) and 
mortality among TB/HIV patients on ART. 
Ha1: There is an association between multimorbidity (disease clusters) and 
mortality among TB/HIV patients on ART 
RQ2: What is the association between demographic factors (sex, age, and marital 
status) and mortality among TB/HIV patients on ART? 
H02: There is no association between demographic factors (sex, age, and marital 
status) and mortality among TB/HIV patients on ART. 
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Ha2: There is an association between demographic factors (sex, age, and marital 
status) and mortality among TB/HIV patients on ART. 
RQ3: What is the association between the phase of TB treatment (initiation and 
continuation) and mortality among TB/HIV patients on ART? 
H03: There is no association between the phase of TB treatment (initiation and 
continuation) and mortality among TB/HIV patients on ART. 
Ha3: There is an association between the phase of TB treatment (initiation and 
continuation) and mortality among TB/HIV patients on ART. 
RQ4: What is the association between the time of initiation of ART (before the 
start of TB treatment and after the start of TB treatment) and mortality among TB/HIV 
patients on ART? 
H04: There is no association between the time of initiation of ART (before the 
start of TB treatment and after the start of TB treatment) and mortality among 
TB/HIV patients on ART. 
Ha4: There is an association between the time of initiation of ART (before the 
start of TB treatment and after the start of TB treatment) and mortality among 
TB/HIV patients on ART. 
RQ5: What is the association between type of TB (pulmonary bacteriologically 
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality among 
TB/HIV patients on ART? 
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H05: There is no association between the type of TB (pulmonary bacteriologically 
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality 
among TB/HIV patients on ART. 
Ha5: There is an association between the type of TB (pulmonary bacteriologically 
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality 
among TB/HIV patients on ART. 
Variables, Types of Data, and Statistical Tests 
The data analysis was focused on analyzing the relationship /association between 
the different variables in each of the research questions. Analysis for hypothesis one was 
focused on the analysis of multimorbidity as an independent variable and mortality as a 
dependent variable. To ensure proper data analysis, new/dummy independent variables 
were derived. All the data on multimorbidity was changed into codes. The coded data 
were entered in the TB/HIV coded form (see appendix). The data was converted into 
dichotomous variables, yes or no. The new variable “yes” l represented the presence, and 
“no” represented the absence of multimorbidity.  
All available data for the key variables is categorical except for age. For example, 
the data for the independent variable of multimorbidity is yes or no. The data for the 
dependent variable of mortality is also “yes” or “no.” Age is a continuous variable and 
was recorded in years. The data for sex was represented as “male” or “female.” The 
marital status data was coded as married, widow, separated or divorced, single or child. 
The table below shows the types of variables, independent and dependent variables, 
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of variable) 
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Data Analysis and Interpretation 
The analysis included univariate analysis, bivariate and multivariable analysis., 
Descriptive measures like the mean, median, mode, interquartile range were used for 
univariate analysis. Also, a full range for continuous data and frequencies for categorical 
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data were used. The confidence intervals were set at 95%, and values were considered 
statistically significant at p= < 0.05.  
According to Creswell (2009), logistics regression measures the relationship 
between categorical dependent variables and one or more independent variables 
(Creswell,2009). To test the hypothesis, logistic regression was used to measure the 
relationship between the presence or absence of multimorbidity, age, sex, marital status, 
phase of TB treatment, the timing of ART initiation, and type of TB, which are 
independent variables, and mortality, which is the dependent variable. The odds ratio was 
used to measure the IVs and mortality as the dependent variable. The confounders were 
tested for using binary logistics regression analysis.  
The potential confounders (covariates) for inclusion in the study were age, sex, 
and marital status (Sangha at al., 2003). Descriptive results were interpreted based on the 
mean, median, frequency, and mode. In this study, the confidence interval was set at 
95%, and all results were interpreted as statistically significant when P=< 0.05. For 
interpretation of the outputs of logistics regression, the odds ratio was used. If the odds 
ratio was higher than one, this meant multimorbidity or other IV is associated with 
mortality than expected. If the odds ratio is less than one, multimorbidity or the other IVs 
were less associated with mortality (Van den Akker et al., 2001).  
Threats to Validity 
Validity is concerned with whether the study can achieve all it is intended to 
achieve through measuring. Is the observed result of the dependent variable (mortality) 
associated with the independent variable’s changes (multimorbidity)? The study is likely 
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to face some threats to validity, including external, internal, and construct validity. These 
threats to validity were controlled to ensure the study results are correct and can be used 
to the general population of TB/HIV patients on ART (Creswell, 2009). The next sections 
elaborate on how external validity, internal validity, and construct validity are likely to 
affect this study and how the threats to validity were minimized.  
External Validity 
External validity relates to whether the study findings were generalizable to the 
general population. The study had external validity if the findings in the selected regional 
referral hospitals could be easily related to the findings in other regional referral hospitals 
(Creswell, 2009). Using a sample that is not representative of the general population 
arising from, for example, selection bias is a critical threat to external validity (Frankfort-
Nachmias & Nachmias, 2008). The attrition of the selected participants during the study 
could lead to having a nonrepresentative sample. The use of secondary data with access 
to a large data sample ensures that the challenge of non representative is overcome. A 
sample size estimation was conducted using G Power Version 3.1.9.2 to obtain an 
adequate sample size for logistic regression for a dichotomous predictor, a significant 
predictor of a binary outcome (mortality), with or without other covariates. . A sample 
size of 2,405 was obtained. The study has adequate power to ensure the results are 
generalizable. 
Internal Validity 
Internal validity is the level to which a researcher can say that the independent 
variable was the cause of the dependent variable. There are several threats to internal 
74 
 
validity during the study that affect experimental studies, including history, maturation, 
statistical regression, experimental mortality, and selection-maturation interaction. These 
threats did not affect this study directly since the study is based on secondary data. Some 
issues that are likely to affect this study include the missing data and missing variables. 
For missing data, some statistical calculations have been developed to ensure this is not a 
problem. In the case of missing variables, there was oversampling to cater for the missing 
variables. Also, all the data captured was as complete as possible.  
Construct Validity 
According to Frankfort-Nachmias and Nachmias, construct validity is where the 
instrument can measure a concept or hypothetical variable or the extent to which the 
measure is theoretically sound (Frankfort-Nachmias & Nachmias, 2008). Statistical 
conclusion validity refers to a situation where the sample size is too small to show any 
effect (Harris, 2010). To overcome the challenge of construct validity, a literature review 
was conducted on the variables to improve the conceptualization of the variables and 
their impact on the measurement. The independent variables multimorbidity, age, sex, 
marital status, phase of TTB treatment, the timing of ART initiation, and type of TB were 
studied and their effect on the mortality dependent variable. The dependent variable for 
this study is the presence or absence of multimorbidity.  
Ethical Procedures 
Permission was obtained from the directors of the regional referral hospitals to 
access TB patient data in the Unit TB registers and, where necessary, ART cards for 
patients. The records were accessed, and data abstracted. All the patient data was de-
75 
 
identified. The data will be stored for at least 5 years if any further analysis needs to be 
done. In this study, patients were not interviewed, and therefore, there was no need for 
using informed consent. 
Regarding secondary data extraction, each participant was given a different 
unique identification number recorded on the data collection tool. During data entry, the 
unique identification number was used, and patient names were deleted. The data was 
kept under lock and key and only be accessed to analyze it for the study purpose. The 
data will be kept for at least 5 years to enable future analysis and only be accessed under 
restricted circumstances.  
Before collecting data, permission was sought from the IRB of Walden University 
(# 01-31-20-0226229) to conduct this study. Also, permission was sought from a local 
IRB Makerere University Higher Degrees Research Ethical Committee (#772). The 
Uganda National Council of Science and Technology (UNCST) is mandated to approve 
any research in the country. Permission was sought from the UNCST (# HS692ES) to 
conduct the study in addition to the local IRB and Walden University IRB. I signed data 
agreements with all the executive directors in all the nine regional referral hospitals. 
Summary 
This section contains a summary of the methodology that was used for this study. 
The purpose of the study was to test and analyze the association between multimorbidity, 
health care processes, and mortality among TB/HIV patients on ART in Uganda. The 
independent variable is multimorbidity, age, sex, marital status, phase of TB treatment, 
time of initiation of ART, and type of TB. The dependent variable was mortality. The 
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study used a quantitative cross-sectional design and applied the review of records in nine 
out of the 14 regional referral hospitals. The target population of the study was TB/HIV 
patients on ART in Uganda. The sample size result was 2,405. Since the response rate 
from previous studies is about 80%, the sample size to use was 2,886 patients. G Power 
was used to calculate the sample size.  
The statistical package for the social sciences (SPSS) for windows version 25 was 
used for data analysis. The data analysis was focused on analyzing the relationship 
/association between the different variables in each of the research questions. The data 
analysis included descriptive and binary logistics regression. The confounders were 
tested using binary logistic regression. Central tendency measures and standard deviation 
were used to interpret descriptive data.  
Straight forward interpretation of data was displayed using tables, graphs, and pie 
charts. Inferential conclusions were drawn from data using the confidence interval set at 
95% and significance level set at P =< 0.05. Any statistically significant results with data 
with P <=0.05 were subjected to biological or social plausibility. Before collecting data, 
permission was sought from the IRB of Walden University, a local IRB, and UNCST as 
required by the country’s laws and regulations. In this study, patients were not 
interviewed, and there was no need for using informed consent. The results are presented 




Chapter 4: Results  
The purpose of the study was to analyze the association between multimorbidity, 
health care processes, and mortality among TB/HIV patients on ART in Uganda. I used 
the health outcomes conceptual framework that allays a complex interplay between the 
health system’s four domains, patient factors, care path, and health outcomes. The 
independent variables were multimorbidity, age, sex, marital status, phase of TB 
treatment, the timing of initiation for ART, and type of TB. The dependent variable was 
mortality. I tested and analyzed the association between multimorbidity, health care 
processes, and mortality among TB/HIV patients on ART. The following were the 
research questions and hypotheses of the study. 
Research Questions and Hypotheses 
RQ1: What is the association between multimorbidity (disease clusters) and 
mortality among TB/HIV patients on ART? 
H01: There is no association between multimorbidity (disease clusters) and 
mortality among TB/HIV patients on ART. 
Ha1: There is an association between multimorbidity (disease clusters) and 
mortality among TB/HIV patients on ART 
RQ2: What is the association between demographic factors (sex, age, and marital 
status) and mortality among TB/HIV patients on ART? 
H02: There is no association between demographic factors (sex, age, and marital 
status) and mortality among TB/HIV patients on ART. 
78 
 
Ha2: There is an association between demographic factors (sex, age, and marital 
status) and mortality among TB/HIV patients on ART. 
RQ3: What is the association between the phase of TB treatment (initiation and 
continuation) and mortality among TB/HIV patients on ART? 
H03: There is no association between the phase of TB treatment (initiation and 
continuation) and mortality among TB/HIV patients on ART. 
Ha3: There is an association between the phase of TB treatment (initiation and 
continuation) and mortality among TB/HIV patients on ART. 
RQ4: What is the association between the time of initiation of ART (before the 
start of TB treatment and after the start of TB treatment) and mortality among TB/HIV 
patients on ART? 
H04: There is no association between the time of initiation of ART (before the 
start of TB treatment and after the start of TB treatment) and mortality among 
TB/HIV patients on ART. 
Ha4: There is an association between the time of initiation of ART (before the 
start of TB treatment and after the start of TB treatment) and mortality among 
TB/HIV patients on ART. 
RQ5: What is the association between type of TB (pulmonary bacteriologically 
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality among 
TB/HIV patients on ART? 
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H05: There is no association between the type of TB (pulmonary bacteriologically 
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality 
among TB/HIV patients on ART. 
Ha5: There is an association between the type of TB (pulmonary bacteriologically 
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality 
among TB/HIV patients on ART. 
In Chapter 4, I describe the data collection methods, the study findings in detail, 
including descriptive results and results from the binary logistics regression. I provide a 
summary of the research questions and a transition to Chapter 5.  
Data Collection 
Several institution review boards approved this study: Walden University IRB (# 
01-31-20-0226229), Makerere University Higher Degrees Research Ethical Committee ( 
#772), and the Uganda National Council of Science and Technology (#HS692ES). The 
MoH provided administrative clearance for the study, and the executive directors of the 
regional referral hospitals signed data use agreements for each hospital. Also, the 
research committees of three hospitals provided additional ethical approval. All these 
documents were presented to the respective hospital authorities at the time of data 
abstraction. 
The experienced health workers in different hospitals abstracted data from Unit 
TB registers, ART cards, and patients’ files onto a data abstraction tool starting in August 
2020, and abstraction was completed on November 20, 2020. The data included a 
hospital’s name, year, unique ID, age, sex, marital status, DR TB status, type of TB, TB 
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treatment outcome, ART number, other medications, and other diseases diagnosed other 
than TB or HIV. The abstraction tool did not include direct identifiers, and patient names 
were not included in the data set. There were no discrepancies in the data collection plan. 
WHO (2020) estimated about 35,000 people living with HIV fell ill with TB in Uganda 
in 2019, with 25,125 notified to WHO, and 25,125 were on ART.  
I used G Power Version 3.1.9.2 to determine the minimum sample size for logistic 
regression for a dichotomous predictor. The following information, including statistical 
power, alpha, and effect size, was used in calculating sample size. The statistical power 
of 80% (0.8) was used to test a relationship between the independent and dependent 
variables. For alpha, I used a predetermined figure of 0.05 to maintain the high power of 
the study. Pr (Y = 1 | X = 1) H1, and I assumed the probability of mortality for TB/HIV 
patients on ART with multimorbidity was H1 = 0.18. Then Pr (Y = 1 | X = 1) H0 = the 
probability of mortality (Y = 1) when someone has no multimorbidities. If the probability 
of mortality for patients without multimorbidity is H0 = 0.09 (TB patients without HIV), 
the two probabilities give an odds ratio of 2.524. Then R squared (R2 other X) = the 
expected squared multiple correlation coefficient (R squared) between the main 
categorical predictor (multimorbidity status) and all other covariates. R squared 
represents the amount of variability in the main predictor (multimorbidity) that is 
accounted for by the covariates. X param π = The proportion of multimorbidity cases and 
are dead; this was estimated at 0.5. The calculated sample size was 2,405. The sample 
size was adjusted to 2,886 to compensate for the 20% missing variables. However, during 
data abstraction, all data on all eligible TB/HIV patients on ART were abstracted from 
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the 9 regional referral hospitals, making 3,580 records. The 3,580 records were adequate 
to answer the research questions. The data were used to make conclusions about the 
mortality, multimorbidity, and health care processes among TB/HIV patients on ART in 
Uganda.  
Results 
The representative sample of the study was 2,880 TB/HIV patients on ART in 
Uganda. As shown in Table 6, 3,580 TB/HIV patients on ART in Uganda were abstracted 
from the nine hospitals. The majority of the TB/HIV patients (95%; 3,402) had 
susceptible TB; only 5% (178) had DR–TB. One hospital had the majority of patients at 
763, while the last had the least patients at 151. A total of 749 (20.9%) of TB/HIV 
patients were dead, while 1016 (28.4%) had at least one multimorbidity, and 344 (30%) 
of those who were dead had multimorbidity. The top five most common multimorbidities 




Regional Referral Hospital Statistics 
Regional referral hospital Code Frequency Percent 
Regional Referral hospital A 0 763 21.3 
Regional Referral hospital B 1 426 11.9 
Regional Referral hospital C 2 490 13.7 
Regional Referral hospital D 3 408 11.4 
Regional Referral hospital E 4 388 10.8 
Regional Referral hospital F 5 316 8.8 
Regional Referral hospital G 6 405 11.3 
Regional Referral hospital H 7 151 4.2 
Regional Referral hospital I 8 233 6.5 






Multimorbidities in TB/HIV Patients on ART  
  Disease category Frequency % 
1 GIT  275 27.1 
2 Nutrition 127 12.5 
3 Respiratory 119 11.7 
4 Neurological 101 9.9 
5 Infectious 74 7.3 
6 Musculoskeletal 44 4.3 
7 Cardiovascular 42 4.1 
8 Renal 36 3.5 
9 Hematological 33 3.2 
10 Dermatological  30 3.0 
11 Endocrine  23 2.3 
12 Reproductive 23 2.3 
13 Immunological 22 2.2 
14 Otorhinolaryngology 18 1.8 
15 Cancer 17 1.7 
16 Liver  16 1.6 
17 Psychological 10 1.0 
18 Lymphatic 6 0.6  
Total 1016 
 
The study had one dependent variable, mortality, and seven independent 
variables: (a) sex, (b) age, (c) marital status, (d) type of TB, (e) ART initiation, (f) TB 
treatment phase, and (g) multimorbidity clusters. All variables were categorical except 
age. Age was measured in years and was the only independent continuous variable. The 
minimum age was 0.42 years; the maximum age was 95 years; the mean age was 36.3 
years, the median age was 36 years, and the mode age was 30 years. Table 8 shows the 
details of the dependent and independent categorical variables. The total sample size was 
3,580 for each variable except age and marital status with 3,579 and 3,245, respectively. 
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Descriptive Statistics for Categorical Variables 
 




Statistic Statistic % 
Mortality 3580 Dependent Alive 0 2831 79.1 
Dead 1 749 20.9 
Sex 3580 Independent Male 0 2087 58.3 
Female 1 1493 41.7 
Marital  
status 
3,245 Independent Married 0 1646 46.0 
Widowed 1 210 5.9 
Divorced/Separated 2 667 18.6 
Single 3 507 14.2 
Child 4 215 6.0 
Missing system - 335 9.4 
Type of TB: 3580 Independent PBC 0 1452 40.6 
PCD 1 1870 52.2 
EPTB 2 258 7.2 
ART Initiation 3580 Independent Before TB treatment 0 2907 81.2 
after TB treatment 1 673 18.8 
Phase of  
TB treatment 
3500 Independent Initial phase 0 564 15.8 
Continuation phase 1 105 2.9 
NA 3 2831 79.1 
Missing system  80 2.2 
Multimorbidity  
clusters 
3580 Independent MM0 0 2564 71.6 
MM1 1 824 23.0 
MM2ormore 2 192 5.4 
 
Evaluating Statistical Assumptions 
I used binary logistic regression to analyze the data set on TB/HIV patients on 
ART in Uganda. As a recommendation, the data should meet all the seven assumptions of 
binary logistics regression before applying the analysis (Laerd, 2017). The first four 
assumptions are concerned with the study’s design, while the other three assumptions are 
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concerned with the nature of data (Laerd, 2017). The requirement is for the data to meet 
all seven assumptions before analyzing using binary logistics regression. 
The study met the assumption1. The first assumption requires that a dichotomous 
dependent variable (DV). The DV for this study is mortality, and it is dichotomous, with 
mortality coded as one and no mortality coded as zero. Assumption 2 was met. 
Assumption 2 required that the independent variables (IV) should either be continuous or 
categorical. This study had seven IVs, one of which was continuous, age measured in 
years. The rest of the six IVs are categorical multimorbidity clusters, sex, marital status, 
time of ART initiation, phase of TB treatment, and type of TB. The study met assumption 
3. Assumption 3 required independent observations and mutually exclusive and 
exhaustive variables. Each observation captured in its row, and the observations have no 
relationship between each and mutually exclusive. All seven variables met this 
assumption. The study met the assumption 4 for only six out of the seven IVs. 
Assumption 4 required that each of the independent variables have at least 15 cases 
(Laerd, 2017). All the independent variables in this study have more than 15 cases each 
except phase of TB treatment. The static count was 3580 for sex, time of art initiation, 
phase of TB treatment and type of TB, and multimorbidity clusters, while marital status 
was 3,245 and age was 3,579. The phase of TB treatment IV had zero cases in the binary 






The Phase of TB Treatment With Fewer Than 15 Cases in the Binary Outcome 
 Code Initial Continuation Completion Total 
No mortality 0 0 0 2831 2831 
Mortality 1 564 105 0 669 
Total  564 105 2831 3500 
 
Assumption 5 was met. Assumption 5 assumed that there should be a linear 
relationship between the independent continuous variables and the logit transformation of 
the categorical dependent variable (Box & Tidwell, 1962). I tested this assumption using 
the Box Tidwell approach. The only continuous independent variable in this study is age. 
I conducted a Box Tidwell procedure to assess the linearity of age (continuous variable) 
against the logit transformation of mortality as a dependent variable (Box & Tidwell, 
1962). The assessment showed that ln -age was not significant (p> 0.05), meaning there 
is a linear correlation between age and the logit transformation of mortality (Laerd, 
2017). Assumption 6 related to multicollinearity was not tested since it is only tested 
when there are many independent study variables. This study had only bivariate 
independent variables without multivariate independent variables. The study satisfied 
Assumption 6. 
The study satisfied Assumption 7 that there no significant outliers. I tested this 
using case wise diagnostics and analyzed each IV against the dependent variable 
mortality. The output did not produce a case wise plot since it had no outliers for the 
independent variables.  
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Statistical Analysis by Research Question 
This section details the statistical analysis of each research question. The 
following is research question one, the null and alternate hypothesis. 
RQ1: What is the association between multimorbidity (disease clusters) and 
mortality among TB/HIV patients on ART? 
H01: There is no association between multimorbidity (disease clusters) and 
mortality among TB/HIV patients on ART. 
Ha1: There is an association between multimorbidity (disease clusters) and 
mortality among TB/HIV patients on ART 
I conducted a binomial logistic regression to test an association between 
multimorbidity (disease clusters) and mortality among TB/HIV patients on ART in 
Uganda. The outcome variable was mortality, while the independent variable was 
multimorbidity. The IV had three levels: (1) no multimorbidity, (2) one multimorbidity, 
and (3) two or more multimorbidities. Mortality was classified as 1 for dead and 0 for 
alive. The logistics regression model was also significant with χ2 (2) = 37.167, p<0.0001. 
The model explained 1.6% (Nagelkerke) of the variance in mortality and correctly 
classified 79.1% of the mortality cases.  
Table 10 shows that the two levels of the independent variables in the model were 
statistically significant. The two levels of the independent variables were one 
multimorbidity cluster and two or more multimorbidity clusters. The TB/HIV patients on 
ART with one multimorbidity were 1.658 times more likely to die (P<0.0001 for each at 
95% CI (1.388 – 1.992) compared to patients with no multimorbidity. The TB/HIV 
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patients on ART with two or more multimorbidities were 1.901 times more likely to die 




Logistics Regression Predicting the Likelihood of Mortality Based on Multimorbidity 
Clusters in TB/HIIV Patients on ART in Uganda 
 B S.E. Wald df Sig. Exp(B) 





  38.217 2 .000    
One multimorbidity 
cluster (MM1) 
.506 .094 29.209 1 .000 1.658 1.380 1.992 
Two or more 
multimorbidity 
cluster (MM2+) 
.642 .166 14.943 1 .000 1.901 1.373 2.633 
Constant –1.497 .051 859.066 1 .000 .224   
Note. The reference variable multimorbidity clusters is no multimorbidity. 
RQ2: what the association between demographic factors (sex, age, and marital 
status) and mortality among TB/HIV patients on ART? 
H02: There is no association between demographic factors (sex, age, and marital 
status) and mortality among TB/HIV patients on ART. 
Ha2: There is an association between demographic factors (sex, age, and marital 
status) and mortality among TB/HIV patients on ART. 
The second research question was answered using a binomial logistic regression 
to test for an association between demographic factors (sex, age, and marital status) and 
mortality among TB/HIV patients on ART in Uganda. The outcome variable was 
mortality, while the independent variables were sex, age, and marital status. Sex coded as 
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male 0 female 1, Age is a continuous variable measure in years, while marital status was 
coded as married 0, widowed 1, separated/divorced 2, single 3, and child 4. Mortality is 
classified as 0 for dead and 1 for alive 0. The logistics regression model was significant 
with χ2 (6) = 10.339, p>0.001 (0.001). The model explained 0.11% (Nagelkerke) of the 
variance in mortality and correctly classified 80.5% of the mortality cases.  
Table 11 shows that the two predictor variables in the model, separated or 
divorced, and single were statistically significant. The TB/HIV patients on ART that were 
separated or divorced were 1.591 times more likely to die (P<0.0001) (0.000); (95% CI: 
1.279 -1.98)1 as compared to married patients. The TB/HIV patients on ART that were 
single were 1.381 times more likely to die (P<0.0001) (0.000); ( 95% CI: 1.069 -1.782) 
as compared to married patients. 
Table 11 
 
Logistics Regression Predicting the Likelihood of Mortality Based on Sex, Marital Status, 
and Age  
 
B S.E. Wald df Sig. Exp(B) 
95% C.I. for EXP(B) 
Lower Upper 
Sex: M = 0, F = 1 (1) –.031 .092 .117 1 .732 .969 .809 1.160 
Marital status         
Married   22.006 4 .000    
Widowed –.110 .215 .263 1 .608 .896 .588 1.364 
Divorced/separated .465 .112 17.309 1 .000 1.591 1.279 1.981 
Single .322 .130 6.106 1 .013 1.380 1.069 1.782 
Child .053 .227 .055 1 .815 1.055 .676 1.645 
Age –.002 .004 .166 1 .684 .998 .990 1.007 
Constant –1.492 .189 62.562 1 .000 .225   
Note. The reference variable for sex is male and for marital status is married. 
RQ3: What is the association between the phase of TB treatment (initiation and 
continuation) and mortality among TB/HIV patients on ART? 
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H03: There is no association between the phase of TB treatment (initiation and 
continuation) and mortality among TB/HIV patients on ART. 
Ha3: There is an association between the phase of TB treatment (initiation and 
continuation) and mortality among TB/HIV patients on ART. 
This question violated the third assumption, which states that each independent 
variable should have more than 15 cases (Laerd, 2017). Three variables had zero alive 
cases for the initial continuation and zero dead cases for completion. The results shown in 




The Phase of TB Treatment With Less Than 15 Cases in the Binary Outcome 
 Code Frequency Percent 
Initial phase 0 564 15.8 
Continuation 1 105 2.9 
Completed treatment 3 2831 79.1 
Missing system - 80 2.2 
Total  3500 97.8 
 
RQ4: What is the association between the time of initiation of ART (before the 
start of TB treatment and after the start of TB treatment) and mortality among TB/HIV 
patients on ART? 
H04: There is no association between the time of initiation of ART (before the 
start of TB treatment and after the start of TB treatment) and mortality among 
TB/HIV patients on ART. 
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Ha4: There is an association between the time of initiation of ART (before the 
start of TB treatment and after the start of TB treatment) and mortality among 
TB/HIV patients on ART. 
For research question four, a binomial logistic regression was conducted to test 
for an association between the time of initiation of ART (before the start of TB treatment 
and after the start of TB treatment) and mortality among TB/HIV patients on ART. The 
outcome variable was mortality, while the independent variable was the time of initiation 
of ART. The time of initiation of ART was categorized as before the start of TB 
treatment coded as 0 and after the start of TB treatment coded as 1. Mortality was 
classified as 1 for dead and 0 for alive. The logistics regression model was also 
significant with χ2 (1) = 31.011(P = 0.000), p<0.001. The model explained 1.3% 
(Nagelkerke) of the variance in mortality and correctly classified 79.1% of the mortality 
cases.  
Table 13 shows that the predictor variables in the model, time of initiation of 
ART, was statistically significantly associated with mortality of TB/HIV patients on 
ART. The TB/HIV patients on ART who began ART treatment after TB treatment were 
1.899 times more likely to die (P<0.0001); ( 95% CI: 1.496 -2.410) than patients who 





Logistics Regression Predicting the Likelihood of Mortality Based on ART Initiation in 
TB/HIV Patients 
 B S.E. Wald df Sig. Exp(B) 
95% C.I. for 
EXP(B) 
Lower Upper 
Time of  
initiation of  
ART  
.641 .122 27.810 1 .000 1.899 1.496 2.410 
Constant –1.868 .113 272.161 1 .000 .154   
Note. The reference variable for the time of initiation on ART is initiation after TB 
treatment. 
RQ5: What is the association between type of TB (pulmonary bacteriologically 
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality among 
TB/HIV patients on ART? 
H05: There is no association between the type of TB (pulmonary bacteriologically 
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality 
among TB/HIV patients on ART. 
Ha5: There is an association between the type of TB (pulmonary bacteriologically 
confirmed, pulmonary clinically diagnosed, and extrapulmonary) and mortality 
among TB/HIV patients on ART. 
To answer the fifth research question, I conducted a binomial logistic regression 
to test an association between Type of TB and mortality among TB/HIV patients on 
ART. The outcome variable was mortality, while the independent variable Type of TB. 
The variable type of TB was coded into three, pulmonary bacteriologically confirmed 
(PBC) = 0, pulmonary clinically diagnosed (PCD) =1 and extrapulmonary (EPTB) =2. 
The logistics regression model was also significant with χ2 (2) = 41.486, p<0.001. The 
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model explained 1.4% (Nagelkerke) of the variance in mortality and correctly classified 
79.1% of the mortality cases.  
Table 14 shows that the two predictor variables in the model, PCD, and EP TB, 
were statistically significant. The TB/HIV patients on ART with PCD were 1.275 times 
more likely to die (P<0.0001 for each; 95% CI: 1.072 -1.518) than patients with PBC. 
The TB/HIV patients on ART with EP TB were 2.355.087 times more likely to die 
(P<0.0001 for each; 95% CI: 1.760 – 3.150) than patients with PBC.  
Table 14 
 
Logistics Regression Predicting the Likelihood of Mortality Based on the Type of TB 
Treatment for TB/HIV Patients on ART 
Category B S.E. Wald df Sig. Exp(B) 










.243 .089 7.516 1 .006 1.275 1.072 1.518 
Extrapulmonary 
(EP) 
.856 .149 33.249 1 .000 2.355 1.760 3.150 
Constant –1.532 .069 498.006 1 .000 .216   
Note. The reference for the type of TB variable was PCD. 
Summary 
This study used cross sectional data from nine out of 14 regional referral 
hospitals. The nine hospitals were systematically selected. The data were extracted from 
all TB/HIV patients on ART registered in 2017, 2018, and 2019 from the Unit TB 
registers and ART cards or ART electronic medical records. The final records collected 
and cleaned were 3,580 records. The study showed significant results for all objectives 
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except objective 3. The study showed that TB/HIV patients on ART, with one 
multimorbidity and two or more multimorbidities, were 1.658 and 1.901 times more 
likely to die than patients with no multimorbidity. The TB/HIV patients on ART that 
were separated or divorced and single were 1.591 and 1.381 times, respectively, more 
likely to die than married patients. Age and sex were not significantly associated with 
mortality. The TB/HIV patients on ART who began ART treatment after TB treatment 
were 1.899 times more likely to die than patients who started ART before TB treatment. 
The TB/HIV patients on ART with PCD and EPTB were 1.275and 2.087 times, 
respectively, more likely to die than patients with PBC. In chapter 5, I interpreted the 
results of the findings, highlight the limitations, significance, and made recommendations 





Chapter 5: Discussion, Conclusions, and Recommendations 
The purpose of the study was to analyze the association between multimorbidity, 
health care processes, and mortality among TB/HIV patients on ART in Uganda. The 
independent variables were multimorbidity, age, sex, marital status, type of TB, phase of 
TB treatment, and timing of initiation for ART. The dependent variable was mortality. 
This study was designed to use quantitative research methods with a cross-sectional 
design, coupled with a retrospective review of medical records from the Unit TB register, 
ART cards, patient files, and electronic medical records.  
The data were cross sectional from nine out of 14 regional referral hospitals. The 
nine hospitals were systematically selected. The data were from all TB/HIV patients on 
ART registered in 2017, 2018, and 2019, in the Unit TB registers and ART cards, patient 
files, or ART electronic medical records. The total of final records collected and cleaned 
were 3,580. The study showed significant results for all objectives except Objective 3. 
TB/HIV patients on ART with one multimorbidity, two or more multimorbidities, 
separated or divorced, and single were associated with mortality. Age and sex were not 
significantly associated with mortality. TB/HIV patients on ART who began ART 
treatment after TB treatment were more likely to die than patients who started ART 
before TB treatment. TB/HIV patients on ART with PCD were more likely to die than 
patients with PBC. TB/HIV patients on ART with EPTB were more likely to die than 
patients with PBC. In Chapter 5, I interpreted the results, highlighted the limitations, 




Interpretation of Findings 
In general, multimorbidity increases premature death risk (AMS, 2018). Studies 
in high-income and middle-income countries have shown that the higher the number of 
multimorbidities, the higher the chances of death (Lix et al., 2016; Nunes et al., 2016; 
Willadsen et al., 2018). There is little literature about multimorbidity and its association 
with mortality among TB/HIV patients on ART (Mchunu et al., 2016; Musaazi et al., 
2019; Stijnberg et al., 2019; Tola et al., 2019). In TB/HIV patients, multimorbidity has 
been postulated to lead to death. However, findings have not always been definitively 
backed by inferential statistics (Mchunu et al., 2016; Musaazi et al., 2019; Stijnberg et al., 
2019; Tola et al., 2019).  
In my study, the results showed that TB/HIV patients on ART with one 
multimorbidity were 1.658 times more likely to die than patients with no multimorbidity. 
The TB/HIV patients on ART with two or more multimorbidities were 1.901 times more 
likely to die than patients with no multimorbidity. The results are aligned to the general 
literature from high-income countries that show that the higher the number of 
multimorbidities, the higher the chances of death (Lix et al., 2016; Nunes et al., 2016; 
Willadsen et al., 2018). However, studies conducted in Africa have concentrated on 
prevalence and multimorbidity patterns rather than their association with mortality (Oni 
et al., 2016; Peltzer et al., 2018). The results of this study add new knowledge to the 
existing body of literature for TB/HIV patients on ART, showing that an increase in 
multimorbidity is associated with mortality. The top 10 multimorbidity clusters included 
gastrointestinal disease, nutritional, respiratory, neurological, infections, musculoskeletal, 
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renal, cardiovascular, hematological, and dermatological diseases. There is a need to 
reexamine current practices, including integrated TB/HIV patient care models and care 
for people with advanced HIV/AIDS disease (WHO, 2017). Stakeholders need to 
improve the screening, diagnostic, and management algorithms to address multimorbidity 
in TB/HIV patients. 
Generally, researchers of marital status have consistently shown that unmarried 
people have poorer health outcomes than married people do (Hilz & Wagner, 2018; 
Kaplan & Kronick, 2006). In this study, the mortality of unmarried individuals, except 
for the widowed, was more likely to happen as compared to married people. The 
unmarried people included those who were divorced, separated, and single. However, the 
widowed population’s mortality compared to the married population was not significant. 
Based on previous research, unmarried people tend to have issues with income, physical 
activity, and social networks, which may predispose them to high mortality (Hilz & 
Wagner, 2018). Several studies have shown that married people use health services more 
than people who are not married (Rutaremwa & Kabagenyi, 2016). In Uganda, widowed 
people could be excluded from this group because they usually have income left by their 
deceased spouse (Rutaremwa & Kabagenyi, 2016). There is a need to pay attention to the 
separated and single if mortality among TB/HIV patients is averted. 
Age and sex were not associated with mortality among TB/HIV patients on ART 
in this study. This finding departs from earlier findings on studies that reflect that sex and 
age are associated with mortality in TB/HIV patients (Englebrecht et al., 2017; Haregu et 
al., 2012). However, some studies have shown no association between mortality, gender, 
97 
 
and age (Lisboa, 2019; Tabarsi et al., 2012). Increasing age is generally associated with 
mortality in developed countries, while some studies in Africa indicate that young age is 
associated with mortality among TB/HIV patients on ART (Englebrecht et al., 2017; Oni 
et al., 2015). Generally, being female is associated with death in developed countries, 
whereas being male is associated with death in TB/HIV patients in Africa (Hood et al., 
2019; Teklu et al., 2017). 
In this study, I also included a variable for the phase of TB treatment (initiation 
and continuation) in testing for mortality among TB/HIV patients on ART. The majority 
of patients completed treatment (79.1%). Among TB/HIV patients on ART who did not 
complete treatment, 15.8% died in the initial phase and 2.9% died in the continuation 
phase. These findings are similar to results in other studies in which more TB/HIV 
patients died in the initial phase of TB treatment than in the continuation phase (Hood et 
al., 2019; Musaazi et al., 2019; Stijnberg et al., 2019). Delay in diagnosis, delay in 
initiation of TB and ART, and IRIS could contribute to mortality (Stijnberg et al., 2019; 
Tola et al., 2019). The results reconfirm that the majority of patients die in the initial 
phase than in the continuation phase. However, it is not clear whether the initial phase or 
continuation phase is statistically associated with mortality. 
Many researchers have found that ART is protective among TB/HIV patients 
(Musaazi et al., 2019; Nagu et al., 2017; Torrens et al., 2016). In this study, the TB/HIV 
patients on ART who began ART treatment after TB treatment were 1.899 times more 
likely to die than patients who started ART before TB treatment. This finding is similar to 
findings in other studies and implies that the earlier the ART begins, the more protective 
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it will be to patients (Musaazi et al., 2019; Nagu et al., 2017; Torrens et al., 2016). Delay 
in the initiation of ART is associated with high mortality, and ART initiation improves 
clinical outcomes (Ford et al., 2018). However, the reasons for high mortality among 
TB/HIV patients on ART need to be explored at the clinical intervention level. 
TB/HIV patients on ART with PCD or EPTB in this study were more likely to die 
than patients with PBC. In this study, I found that TB/HIV patients on ART with PCD or 
EPTB were 1.275 and 2.087 times, respectively, more likely to die than patients with 
PBC. The results are similar to results from researchers in Uganda and Ethiopia who 
found that patients with PCD and EPTB were more likely to die than patients with PBCs 
(Biruk et al., 2016; Lisboa et al., 2019; Musaazi et al., 2019; Tola et al., 2019). The 
higher mortality among PCD and EPTB than PBC may be due to delay in diagnosing 
PCD and EPTB, which may take more than a month (Lisboa et al., 2019). 
In this study, I used the health outcomes model with four domains: characteristics 
of the health care system, patient characteristics, health care path, and patients 
outcomes(Canadian Institute for Health Information, 2008). The health outcomes 
conceptual framework was used because of its simplicity in studying patient-level 
outcomes. The independent variables were part of only two domains of the study, patient 
characteristics (sex, age, marital status, multimorbidity) and health care path (timing of 
ART and phase of TB treatment) that were direct predictors of patient outcomes 
(mortality). However, patient characteristics (sex, age, marital status, and multimorbidity) 
were also indirect predictors of patient outcomes (Sbagiria et al., 2016).  
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The study results are in line with the health outcomes conceptual framework. The 
independent variables—patient characteristics (marital status, multimorbidity) and health 
care path (timing of ART and phase of TB treatment)—were direct predictors of 
mortality as reflected in the statistically significant results. In this study, age and sex were 
not statistically significant and therefore not predictors of mortality. Age and sex could 
have been indirect predictors of mortality; however, this prediction was not proven in this 
study. The health outcomes model is used in public health to predict and improve patient 
outcomes. The conceptual framework is also used as a TB/HIV framework to monitor 
and evaluate TB/HIV activities (WHO, 2015). The framework has also been used in 
health outcomes research, primarily for the Hepatitis C virus (Sbagiria et al., 2016).  
Limitations of the Study 
In this study, the health outcomes conceptual framework was used that has four 
domains. However, only three domains were used to study patient characteristics, health 
care path, and patient outcomes. The health systems care domain was not studied. In 
addition, a few factors from the three domains were studied as represented by the 
independent variables (multimorbidity, age, sex, marital status, type of TB, phase of TB 
treatment, and timing of initiation for ART) and dependent variable (mortality). Despite 
this limitation, the study brought out new findings on the association of multimorbidities 
and mortality. The study has also shown consistent results with other studies (Musaazi et 
al., 2019; Nagu et al., 2017; Torrens et al., 2016;). The need for future studies to be 
designed to include more factors that are missing in this study is conspicuous. 
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This study used routine data from Unit TB registers, ART cards, HIV patient files, 
and electronic medical records. Secondary routine data usually have missing records. 
Patients who had incomplete data on the outcome variable were left out, especially for 
patients registered at the regional referral hospital for TB care but receiving ART at 
peripheral health facilities. Also, patients with other unfavorable outcomes like the loss to 
follow-up and non evaluated were left out since the outcome variable was binary with 
dead or alive. However, all independent variables were captured, including marital status 
and age, which had missing data. Another limitation could be about diagnostic errors. 
The diagnostic tests depended on the equipment used to make the diagnostic tests during 
routine care. The accurate and correct records depended on the clinician. To minimize 
this error, the health workers abstracted data from primary data tools filled by the 
clinician during service delivery. 
Although these limitations exist, this study’s strength was using the large sample 
size of 3,580 patients and systematic sampling from nine out of 14 patients. The large 
sample size and systematic sampling improved the internal and external validity of the 
study. The study design was appropriate for the research questions to highlight the 
significant findings related to death among TB/HIV on ART. The study findings can be 
generalized to TB/HIV patients on ART with associated mortality in Uganda and similar 
settings.  
Recommendations 
Mortality for TB/HIV patients on ART is an outcome with some known 
confounders that were not part of the TB and ART tools. These included socioeconomic 
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characteristics and behavioral factors (Tola et al., 2019). The socioeconomic factors left 
out include income, social support, and education status. The behavioral factors left out 
were alcohol consumption and cigarette smoking. These variables would have further 
supported the explanation of mortality on TB/HIV patients on ART. In the future, 
prospective studies collecting primary data should include all the relevant variables on all 
socioeconomic factors (income, social support, education status) and behavioral factors 
(alcohol consumption, cigarette smoking).  
I did not include some treatment and disease related factors like adherence of 
patients on ART and TB treatment, CD4 cell testing, and viral load. There is a need for 
future research to check for an association between patient adherence to ART and TB 
treatment, CD4 cell testing, viral load, and mortality in TB/HIV patients on ART. The 
results would inform HIV and TB programs on interventions to protect TB/HIV patients 
from death and interventions to protect HIV patients on ART from developing advanced 
HIV disease. A prospective rather than a retrospective research study could be conducted 
with a clear intention to follow up the well-documented multimorbidities among TB/HIV 
patients on ART. 
In this study, I did not cover individual multimorbidities. Multimorbidity was 
studied as disease clusters. There is a need to understand further the individual diseases 
and how they are associated with mortality in TB/HIV patients on ART. Such a study 
would provide vital information on how patient-family-centered care can be delivered to 




Health stakeholders can use the significant findings that arise from the study to 
influence positive social change with an impact on the lives of patients, families, and 
communities. This study showed significant findings that several multifaceted factors are 
associated with mortality among TB/HIV patients on ART in Uganda. The policymakers, 
managers in governments, and NGOs should advocate for change in policy, practice, and 
research at different levels, including networks of TB patients coinfected with TB. This 
study has developed new knowledge; there is an association between multimorbidity 
(disease clusters) and mortality among TB/HIV patients on ART. All patients with 
multimorbidity need appropriate care to avoid mortality. In previous studies, patient–
family-centered care was beneficial to patients with multimorbidity (Boyd & Fortin, 
2010). The dually infected TB/HIV patients on ART that have multimorbidity will need 
patient-family-centered care. The health managers need to advocate for patient – family-
centered care at all healthcare levels, including the patient, family, and healthcare teams 
(Boyd& Fortin, 2010). 
Furthermore, the study showed that mortality in TB/HIV patients on ART was 
associated with those who were separated or divorced and single (Robards et al., 2012). 
The health workers managing patients have to think about the families and making sure 
those who are either separated, divorced, and single are given appropriate nonclinical 
care at the TB/HIV clinics. Also, the TB/HIV patients on ART who began ART treatment 
after TB treatment were 1.899 times more likely to die than patients who started ART 
before TB treatment. Care providers should prioritize and closely monitor all patients 
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who start ART late for care at the health facilities to make sure they do not die. The 
TB/HIV patients on ART with PCD and EPTB were 1.275 and 2.087 times, respectively, 
more likely to die than patients with PBC. Extra care has to be taken by health care 
workers to screen for PCD and EPTB in TB/HIV patients on ART in patient-family-
centered care. Also, community TB/HIV services have to target patients with 
multimorbidity, separated/ divorced or single, with PCD or EPTB, and those who start 
ART after TB treatment. 
The TB and HIV programs should implement patient-family-centered care at the 
health facility and community levels in line with universal health coverage principles 
described by WHO under the sustainable development goals. The TB and HIV programs 
should screen and treat all TB/HIV patients with advanced HIV disease who have other 
diseases, including GIT, nutritional, respiratory, neurological, and infections, 
musculoskeletal, renal, cardiovascular. The two programs should endeavor to identify 
patients who are single, separated, or divorced, with EPTB or PCD, who started ART 
after TB treatment and ensure they get appropriate care. Finally, sexual contacts of 
people with HIV may have HIV and TB. The HIV programs should screen for HIV 
among all sexual contacts of TB/HV patients, which helps identify new HIV patients 
early and start treatment before they get TB. Screening household contacts of all TB/HIV 
patients for TB is already a practice that should continue. 
Conclusions 
This study contributed to new knowledge, confirmed the findings from previous 
studies, and presented findings that differed from the findings of other studies about 
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multimorbidity, health care processes, and mortality among TB/HIV patients on ART. 
The new knowledge: TB/HIV patients on ART with one or more multimorbidities were 
more likely to die than patients with no multimorbidity. Based on the existing literature, 
no TB/HIV study brought out this critical finding. The policymakers and practitioners 
should use this new knowledge to guide the management of multimorbidities among 
TB/HIV patients on ART to prevent premature deaths.  
The study has also confirmed the findings from previous studies. The TB/HIV 
patients on ART that were separated/divorced or single were 1.591 and 1.381 times, 
respectively, more likely to die than married patients. This finding is similar to 
knowledge generated from other general studies and studies on TB and TB/HIV. Looking 
out for unmarried people to minimize mortality among TB/HIV patients on ART is a 
priority. More to this finding, TB/HIV patients on ART who began ART treatment after 
TB treatment were 1.899 times more likely to die than patients who started ART before 
TB. ART has always been protective in HIV and TB/HIV patients, especially when it 
started early (Musaazi et al., 2019). The practitioners should endeavor to start ART as 
soon as possible in TB/HIV patients (WHO, 2017). 
The study has also presented findings that differed from the findings of other 
studies. Age and sex were not significantly associated with mortality, unlike in other 
studies, where mortality was associated with age and sex. All these findings highlight the 
need for implementation of patient-family-centered care at the health facility and 
community levels. More studies are needed to understand further the individual 
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multimorbidities associated with mortality and how patient-family-centered care can be 
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